

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
7 April 2005 (07.04.2005)

PCT

(10) International Publication Number  
**WO 2005/031362 A2**

(51) International Patent Classification<sup>7</sup>: G01N 33/68

(21) International Application Number:  
PCT/IL2004/000898

(22) International Filing Date:  
27 September 2004 (27.09.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/507,488 2 October 2003 (02.10.2003) US  
60/550,334 8 March 2004 (08.03.2004) US

(71) Applicant (*for all designated States except US*): RAMOT  
AT TEL AVIV UNIVERSITY LTD. [IL/IL]; 32 Haim  
Levanon Street, 69 975 Tel Aviv (IL).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): GAZIT, Ehud  
[IL/IL]; 32 Trumpeldor Street, 47264 Ramat Hasharon  
(IL). CHERNY, Izhack [IL/IL]; 30 Pines Street, 49 572  
Petah-Tikva (IL).

(74) Agent: G.E. EHRLICH (1995) LTD.; 11 Menachem Be-  
gin Street, 52 521 Ramat Gan (IL).

(81) Designated States (*unless otherwise indicated, for every  
kind of national protection available*): AE, AG, AL, AM,  
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,  
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,  
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,  
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,  
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,  
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,  
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,  
ZW.

(84) Designated States (*unless otherwise indicated, for every  
kind of regional protection available*): ARIPO (BW, GH,  
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,  
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,  
FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,  
SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,  
GW, ML, MR, NE, SN, TD, TG).

Published:

— *without international search report and to be republished  
upon receipt of that report*

*For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.*

(54) Title: NOVEL ANTIBACTERIAL AGENTS AND METHODS OF IDENTIFYING AND UTILIZING SAME

(57) Abstract: A method of identifying a molecule capable of inducing death of a bacterial cell which includes exposing toxin and antitoxin polypeptides of a toxin-antitoxin pair produced by the bacterial cell to a plurality of molecules, and identifying a molecule of the plurality of molecules capable of preventing or disrupting binding between the antitoxin and said toxin polypeptides, thereby identifying the molecule capable of inducing death of the bacterial cell.

WO 2005/031362 A2

## NOVEL ANTIBACTERIAL AGENTS AND METHODS OF IDENTIFYING AND UTILIZING SAME

### FIELD AND BACKGROUND OF THE INVENTION

5       The present invention relates to methods of identifying antibacterial agents and more particularly, to novel antibacterial agents which are capable of preventing or disrupting binding between antitoxin and toxin polypeptides of bacterial cells.

      Presently, treatment of infections caused by pathogenic bacteria relies predominantly on the administration of antibiotics. Antibiotics currently being used  
10       against bacterial pathogens include  $\beta$ -lactams (e.g., penicillin and cephalosporin) and glycopeptides (e.g., vancomycin and teichoplanin), which act to inhibit the final step in peptidoglycan synthesis, quinolones, which inhibit bacterial DNA replication, inhibitors of bacterial RNA polymerase such as rifampin, and aminoglycosides (e.g., kanamycin and gentamycin). Other well-known antibiotics include inhibitors of  
15       enzymes participating in production of tetrahydrofolate (e.g., sulfonamides).

      Despite being successful in controlling or eliminating bacterial infections, widespread use of antibiotics both in human medicine and as a feed supplement in poultry and livestock production has led to drug resistance in many pathogenic bacteria (McCormick J. B., Curr Opin Microbiol 1:125-129, 1998) and as such, the  
20       effectiveness of such antibiotics has greatly diminished in the last decade.

      The rapid and widespread development of resistance in pathogenic bacteria is illustrated by the fact that presently almost half of the clinical strains of *Haemophilus ducreyi*, the causative agent of chancroid, carry genes which confer resistance to amoxicillin, ampicillin and a series of other  $\beta$ -lactams (Prachayasittikul  
25       *et al.*, Southeast Asian J Trop Med Public Health 31:80-84, 2000). Likewise, the incidence of resistance towards tetracyclines among clinical strains of *Salmonella typhimurium* has increased from zero in 1948 to 98% by 1998 (Teuber M., Cell Mol Life Sci 30:755-763, 1999).

      The economic impact of managing infections caused by antibiotic-resistant  
30       bacteria is substantial, and current costs are estimated to be more than \$4 billion annually [Harrison and Lederberg (ed.), Antimicrobial resistance: issues and options. National Academy Press, Washington, D.C. pp. 1-7, 1998]. Furthermore, as resistance spreads among bacteria, there is grave concern that antibiotics treatment

will become increasingly less effective and, in some cases, completely ineffective.

This rapidly increasing appearance of bacterial resistance to antibiotics has driven researchers to search for new agents that possess activity against antibacterial drug-resistant strains. Although several approaches can be utilized to achieve this goal, the most generalized would be the discovery and clinical development of an agent that acts on a new target which has not yet experienced selective pressure in the clinical setting. Such a target should be essential to the growth and survival of bacteria and be sufficiently different from similar macromolecules present in the human host (Goldman and Gange, *Curr Med Chem* 7:801-820, 2000).

The Toxin-antitoxin complex of bacteria includes a pair of polypeptides that is encoded by bacterial plasmids and chromosomes. It is postulated that in bacteria these polypeptides function to induce programmed cell death or growth inhibition in response to starvation or other adverse conditions (Hayes, *Science* 301:1496-1499, 2003). The antitoxins neutralize the cognate toxins by forming tight complexes therewith. The antitoxins are unstable due to degradation by cellular proteases (e.g., Lon or Clp), whereas toxins are stable polypeptides. Toxin-antitoxin pair examples include the *pemI-pemK* genes of plasmid R100, the *phd-doc* genes of phage P1, and the *ccdA-ccdB* genes of plasmid F (Couturier *et al.*, *Trends Microbiol.* 6:269-275, 1998; Engelberg-Kulka and Glaser, *Annu. Rev. Microbiol.* 53:43-70, 1999; Jensen and K. Gerdes, *Mol. Microbiol.* 17:205-210, 1995). Toxin-antitoxin pairs are thought to increase the stability of extrachromosomal elements by selectively killing plasmid-free cells, resulting in the proliferation of plasmid-harboring cells in the population (Holcik and Iyer, *Microbiology* 143:3403-3416, 1997; and Grady and Hayes, *Mol. Microbiol.* 47:1491-1432, 2003). Several toxin-antitoxin encoding gene analogues have been identified on the *E. coli* K-12 chromosome, such as *mazE-mazF* (also known as *chpAI-chpAK*), *sof-gef*, *kicA-kicB*, *relB-relE*, *chpBI-chpBK* and *yefM-yoeB* (Grady and Hayes, *Mol. Microbiol.* 47:1491-1432, 2003; Aizenman *et al.*, *Proc. Natl. Acad. Sci. USA* 93:6059-6063, 1996; Feng *et al.*, *Mol. Gen. Genet.* 243:136-147, 1994; Gotfredsen and Gerdes, *Mol. Microbiol.* 29:1065-1076, 1998; Masuda *et al.*, *J. Bacteriol.* 175:6850-6856, 1993; and Poulsen *et al.*, *Mol. Microbiol.* 3:1463-1472, 1989).

Although the use of toxin encoding polynucleotides for inducing bacterial cell death has been recently suggested (Westwater *et al.*, Antimicrobial Agents and Chemotherapy 47: 1301-1307, 2003), the prior art does not teach or suggest prevention or disruption of toxin-antitoxin binding for the purpose of inducing death  
5 in bacterial cells.

While reducing the present invention to practice, the present inventors have identified the site of interaction between bacterial toxin and antitoxin polypeptides thus enabling for the first time to identify or design novel antibiotics which target this site of interaction and thus enable bacterial cell killing.

10

### SUMMARY OF THE INVENTION

According to one aspect of the present invention there is provided a method of identifying a molecule capable of inducing death of a bacterial cell. The method includes (i) exposing toxin and antitoxin polypeptides of a toxin-antitoxin pair  
15 produced by the bacterial cell to a plurality of molecules; and (ii) identifying a molecule of the plurality of molecules capable of preventing or disrupting binding between the antitoxin and the toxin polypeptides.

According to another aspect of the present invention there is provided a method of treating an infection of bacteria in a subject. The method includes  
20 preventing or disrupting binding between a toxin and an antitoxin polypeptides of a toxin-antitoxin pair produced in the bacteria.

According to yet another aspect of the present invention there is provided a pharmaceutical composition for treating an infection of bacteria which includes an effective amount of an agent capable of preventing or disturbing binding between a  
25 toxin and an antitoxin polypeptides of a toxin-antitoxin pair produced in the bacteria.

According to still another aspect of the present invention there is provided a method of identifying toxin and antitoxin polypeptides of a toxin-antitoxin pair. The method includes (i) identifying bacterial polynucleotide sequences at least partially homologous to polynucleotide sequences encoding known bacterial toxin and  
30 antitoxin polypeptides to thereby obtain a plurality of toxin and antitoxin encoding sequences; and (ii) determining a chromosomal position of each of the plurality of sequences, wherein toxin and antitoxin encoding sequences which are chromosomally

positioned at a distance from each other which is no greater than a predetermined value encode a toxin-antitoxin pair.

According to further features in preferred embodiments of the invention described below, exposing toxin and antitoxin polypeptides of a toxin-antitoxin pair produced by the bacterial cell to a plurality of molecules is effected by administering the plurality of molecules to bacteria expressing the toxin and antitoxin polypeptides.

According to still further features in the described preferred embodiments, the antitoxin polypeptide is an unfolded polypeptide.

According to still further features in the described preferred embodiments, the antitoxin polypeptide includes an amino acid sequence selected from the group consisting of SEQ ID NOs. 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122 and 124.

According to still further features in the described preferred embodiments, the antitoxin polypeptide is encoded by a polynucleotide sequence selected from the group consisting of SEQ ID NOs. 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64 and 66.

According to still further features in the described preferred embodiments, the toxin polypeptide includes an amino acid sequence selected from the group consisting of SEQ ID NOs. 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 93, 95, 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, 123 and 125.

According to still further features in the described preferred embodiments the toxin polypeptide is encoded by a polynucleotide sequence selected from the group consisting of SEQ ID NOs. 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65 and 67.

According to still further features in the described preferred embodiments, preventing or disrupting binding between the toxin and the antitoxin polypeptides is effected by providing to the subject an agent selected from the group consisting of (i) a compound which specifically binds to the antitoxin or to the toxin; (ii) an antisense polynucleotide capable of specifically hybridizing with an mRNA transcript encoding the antitoxin; (iii) a ribozyme which specifically cleaves transcripts encoding the antitoxin; and (iv) a small interfering RNA (siRNA) molecule which specifically cleaves the antitoxin transcripts.

According to still further features in the described preferred embodiments the compound is selected from the group consisting of a peptide, a polynucleotide, a polysaccharide, a small organic compound and a non-biological compound.

According to still further features in the described preferred embodiments  
5 the compound which specifically binds to the antitoxin is an antibody or an antibody fragment.

According to still further features in the described preferred embodiments the bacteria are pathogenic bacteria.

According to still further features in the described preferred embodiments the  
10 subject is a mammal.

According to still further features in the described preferred embodiments the subject is a human.

According to still further features in the described preferred embodiments the peptide is derived from the toxin or from the antitoxin.

According to still further features in the described preferred embodiments the  
15 peptide includes an amino acid sequence selected from group consisting of SEQ ID NOs: 7-9.

According to still further features in the described preferred embodiments, the agent is a polynucleotide capable of specifically hybridizing with an mRNA transcript  
20 encoding the antitoxin.

According to still further features in the described preferred embodiments, the agent is a ribozyme which specifically cleaves transcripts encoding the antitoxin

According to still further features in the described preferred embodiments, the agent is a small interfering RNA (siRNA) molecule which specifically cleaves the  
25 antitoxin transcripts

According to still further features in the described preferred embodiments, the predetermined value is ranging between 10 base pair to 150 base pair.

The present invention successfully addresses the shortcomings of the presently known configurations by providing methods of identifying novel  
30 antibacterial agents which are capable of preventing or disrupting binding between antitoxin and toxin polypeptides of bacterial cells and pharmaceutical compositions comprising these agents for treating bacterial infections.

### BRIEF DESCRIPTION OF THE DRAWINGS

The invention is herein described, by way of example only, with reference to the accompanying drawings. With specific reference now to the drawings in detail, it is stressed that the particulars shown are by way of example and for purposes of illustrative discussion of the preferred embodiments of the present invention only, and are presented in the cause of providing what is believed to be the most useful and readily understood description of the principles and conceptual aspects of the invention. In this regard, no attempt is made to show structural details of the invention in more detail than is necessary for a fundamental understanding of the invention, the description taken with the drawings making apparent to those skilled in the art how the several forms of the invention may be embodied in practice.

In the drawings:

FIG. 1 illustrates *yoeB* and *yefM* pair homologue sequences identified in different bacterial genomes. These homologue sequences were separated by less than 100 base pairs in their respective bacterial genomes and thus were selected for further analysis. The black half-ovals represent *yefM* homologues and the gray half-ovals represent *yoeB* homologue sequences. The sharp gray arrowheads represent *doc* homologue sequences. Missing gi numbers indicate annotated open reading frames (ORFs).

FIG. 2A illustrates a multiple sequence alignment of YefM polypeptide homologues. The alignment list includes 30 sequences from 25 different bacteria (different homologues which exist in the same bacteria are presented in alphabetical order). Polypeptide sections having sequence identity of  $\geq 80\%$ ,  $\geq 60\%$  and  $\geq 40\%$  are colored in dark, medium and light blue background, respectively. The identity percentage values were determined by using a BLOSUM62 matrix.

FIG. 2B illustrates a multiple sequence alignment of YoeB polypeptide homologues. Polypeptide sections having sequence identity of  $\geq 80\%$ ,  $\geq 60\%$  and  $\geq 40\%$  are colored in dark, medium and light blue background, respectively. The identity percentage values were determined by using a BLOSUM62 matrix. The upper alignment list illustrates 26 amino acid sequences obtained from 22 different bacteria, all showing substantial homology to the YoeB polypeptide. The lower alignment list illustrates three Doc homologue sequences.

FIGs 3A-G illustrate the function of the YoeB and YefM polypeptides as a toxin-antitoxin pair *in vivo*. Bacteria (*E. coli* strain TOP10) expressing YefM only (Figures 3A and 3D), expressing YoeB only (Figures 3B and 3E), or expressing YoeB and YefM combined (Figures 3C and 3F), were grown in LB-Amp at 37 °C.

5 Transcription of the polypeptides was induced by supplementing 0.2% L-arabinose (full circles) to the stationary growth phase at time zero (Figures 3A-C), or at the logarithmic growth phase, when cultures reached an OD<sub>600</sub> of 0.45 (Figures 3D-F). As a negative control, parallel cultures were supplemented with 0.2% glucose (open circles). Figure 3G illustrates the effect of overexpressing YefM alone, YoeB alone,

10 or YoeB and YefM combined, on bacterial colony formation. Bacterial suspension droplets were added, in serial ten-fold dilutions, onto solid media supplemented with different concentrations of L-arabinose (0%, 0.0005%, 0.005%, 0.02%, 0.05%, 0.1%, and 0.2%) and incubated at 37°C for 20 hours. Cultures missing L-arabinose were supplemented with 0.2% glucose. The resulting colony formation of bacteria

15 expressing YoeB alone was inversely proportional to L-arabinose concentrations, while colony formation of bacteria expressing YoeB and YefM combined was unaffected by the L-arabinose concentration.

FIGs. 4A-D illustrate the native unfolded state of the YefM antitoxin polypeptide. Figure 4A shows spectra of far UV circular-dichroism (CD) of YefM in PBS (pH 7.3) at 25 °C (---), 37 °C (—), and 42 °C (— —), indicating a random

20 coil structure. Figure 4B illustrates spectra of Fourier Transform Infrared of the YefM polypeptide having a minimum transmittance at wave-number of 1643 cm<sup>-1</sup>, indicating a random coil structure. Figure 4C illustrates the thermal stability of YefM at 2 °C to 80 °C temperature range. The thermal stability of YefM was

25 determined by monitoring CD ellipticity at 217 nm (triangles) and 222 nm (circles) as a function of temperature. Figure 4D shows an SDS-PAGE analysis illustrating solubility of the YefM polypeptide which survived a boiling treatment. The left lane illustrates SDS-PAGE of YefM-GST sample following cleavage. The right lane illustrates an SDS-PAGE of the supernatant of the same sample following boiling for

30 10 minutes and centrifugation.

FIG. 5A illustrates the relative occurrence of amino acids in YefM family of polypeptides, in relation to the general occurrence of amino acids in polypeptide



compositions [based on NCBI proteins database (22)]. Error bars represent standard deviations and the asterisks indicate statistically significant differences at  $P < 0.001$ . This figure illustrates that the YefM family of polypeptides are uniquely enriched in the amino acids M and E and uniquely depleted in the amino acids W, C, P, F and G.

5        FIG. 5B illustrates the calculated net charge and hydrophobicity of polypeptide homologues of YefM (circles) and Phd (triangles). The solid line represents Uversky *et al.* model (3) separating presumptive unfolded polypeptides (upper left area) from folded polypeptides (bottom right area).

FIGs. 6A-C are peptide array analyses identifying a YefM derivative which  
10        contains the antitoxin binding determinant. Figure 6A illustrates an array of tridecamer peptides corresponding to consecutive overlapping sequences of 92 amino acids of the YefM polypeptide (two amino-acids shift between peptides). A YoeB-GST bound to the membrane is positively identified in YefM<sub>11-23</sub>-YefM<sub>15-27</sub>, YefM<sub>33-45</sub>, YefM<sub>75-87</sub> and YefM<sub>77-89</sub> peptides. Figure 6B illustrates a similar array of  
15        peptides corresponding to consecutive overlapping sequences of YefM<sub>8-31</sub>, YefM<sub>29-48</sub>, and YefM<sub>72-92</sub> (single amino-acid shift between peptide), indicating that the best binding of YoeB-GST was to YefM<sub>11-23</sub>. Figure 6C illustrates of YefM<sub>11-23</sub> analogs having single amino acid replacements. YefM<sub>11-23</sub> analogs having arginine in position 19 of the YefM<sub>11-23</sub> sequence, which was replaced with either alanine or  
20        glycine, were unable to bind YoeB-GST.

FIGs. 7A-B illustrate the instability of the YefM antitoxin *in vivo*. Expression of YefM in *E. coli* TOP10 was briefly induced then repressed. Following repression, samples taken sequentially at different time intervals were analyzed for YefM expression by western blot analysis (Figure 7A) and by  
25        densitometer (Figure 7B), indicating a half-life of about one hour for this polypeptide.

FIG. 8 is a surface plasmon resonance (SPR) analysis illustrating binding of GST-YoeB fusion polypeptide to the YefM<sub>11-23</sub> peptide which contains the YefM binding determinant. SPR sensorgrams show the change in binding response (in  
30        RU) upon injection of 12.5, 25 and 50 nM of GST-YoeB in 50 mM Tris-HCl (pH 7.2) running buffer over the YefM<sub>11-23</sub> peptide.

FIGs. 9 A-C illustrate chromatography analyses indicating a tight binding

between YoeB-His and YefM. Figure 9A shows a co-elution of YefM and YoeB-His in a nickel affinity column chromatography. Figure 9B shows a co-elution of YefM and YoeB-His resulting from an anion-exchange column developed with NaCl gradient. Figure 9C shows a co-elution of YefM and YoeB-His resulting from a C<sub>18</sub> HPLC reverse-phase column developed with acetonitrile gradient.

FIGs. 10A-C illustrate the structure and stability of the YoeB toxin. Figure 10A shows spectra of far UV circular-dichroism (CD) of 2.5  $\mu$ M YoeB-His monitored at 4 °C, 37 °C and 4 °C after 37 °C, indicating a predominant  $\alpha$ -helical structure. Figure 10B shows spectra of Near-UV CD of 10  $\mu$ M YoeB-His monitored at 4° C and 37° C, indicating that no structural changes of the polypeptide occurred within that temperature range. Figure 10C illustrates the thermal stability of YoeB-His at thermal melt and return range of 2 $\pm$ 80 °C. The thermal stability of YoeB-His was determined by monitoring CD ellipticity at 222 nm as a function of temperature.

FIGs. 11A-C illustrate the thermal melting point of YoeB. Figure 11A illustrates the CD ellipticity of YoeB-His as a function of temperature at 2 $\pm$ 37 °C. Figure 11B illustrates the CD ellipticity of YoeB-His as a function of temperature at 2 $\pm$ 56 °C. Figure 11C illustrates the CD ellipticity of YoeB-His as a function of temperature at 2 $\pm$ 60 °C, indicating that YoeB undergoes thermal denaturation at approximately 60 °C.

#### DESCRIPTION OF THE PREFERRED EMBODIMENTS

The present invention is of methods of identifying agents capable of preventing or disrupting binding between antitoxin and toxin polypeptides in bacterial cells, and of pharmaceutical compositions which include such agents and their use for treating bacterial infections.

The principles and operation of the present invention may be better understood with reference to the drawings, examples and accompanying descriptions.

Before explaining at least one embodiment of the invention in detail, it is to be understood that the invention is not limited in its application to the details of construction and the arrangement of the components set forth in the following description or illustrated in the drawings and the examples. The invention is

capable of other embodiments or of being practiced or carried out in various ways. Also, it is to be understood that the phraseology and terminology employed herein is for the purpose of description and should not be regarded as limiting.

As is discussed hereinabove, toxin-antitoxin polypeptide pairs are often  
5 present in bacterial cells. Although their function in such cells is not clear, it has been conclusively shown that antitoxin polypeptides bind to their cognate toxins to thereby neutralizing their cytotoxic activity in bacterial cells.

Using bioinformatic tools, the present inventors uncovered that homologues of the YoeB-YefM toxin-antitoxin pair exist in a wide range of bacteria, including  
10 several pathogenic bacteria. Biochemical analysis has revealed that the YefM antitoxin is an unfolded polypeptide in its native state within bacterial cells. Further analysis using an isolated peptide derivative of YefM (YefM<sub>11-23</sub>; set forth in SEQ ID NO: 7) identified the determinant sequence of YefM which is involved in YoeB toxin binding; surprisingly, an alteration of just one amino acid of the YefM<sub>11-23</sub> is  
15 sufficient to completely abolish this binding (see in Examples 1-6 hereinbelow). It was thus concluded that binding between the YoeB toxin and the YefM antitoxin polypeptides relies upon a highly specific recognition which can be readily prevented or disrupted.

Thus, according to one aspect of the present invention, there is provided a  
20 method of treating a bacterial infection in a subject, such as a mammal, preferably, a human.

The method is effected by preventing or disrupting binding between toxin and antitoxin polypeptides of toxin-antitoxin pairs produced in the bacteria responsible for infection.

25 The bacteria can be any bacteria which produces a toxin-antitoxin pair. Preferably, the bacteria are *Enterococcus faecium*, *Klebsiella pneumoniae*, *Mycobacterium tuberculosis*, *Salmonella typhimarium*, *Streptococcus pneumoniae*, *Yersinia enterocolitica* and *E. coli*.

The toxin-antitoxin pair can be any pair of polypeptides encoded by a  
30 plasmid or chromosome of the bacteria responsible for the infection. Specific examples of toxin-antitoxin pairs are provided in Table 1 and in the Examples section hereinbelow.

The phrase "preventing or disrupting" used herein refers to precluding binding between toxin and antitoxin polypeptides, or to disassociating a complex formed therefrom. As further described hereinbelow, such prevention or disruption can be effected by reducing expression of the antitoxin, or by reducing the antitoxin-toxin binding capacity.

Preventing or disrupting binding of a toxin-antitoxin pair can be effected using any one of several approaches.

In one approach, disrupting binding of a toxin-antitoxin pair is effected by providing to the subject an agent which specifically binds to the antitoxin, or, preferably, to the antitoxin binding determinant.

The binding determinant sequence of the antitoxin can be identified using techniques well known in the art including, but not limited to, peptide array analysis and surface plasmon-resonance analysis. Example 6 illustrates the isolation of a peptide derivative of the YefM antitoxin which includes the YefM antitoxin binding determinant (set forth in SEQ ID NO: 7). It will be appreciated that such characterization of the antitoxin binding determinant enables identification or design of a compound capable of preventing or disrupting the binding between toxin and antitoxin polypeptides. For example, using this determinant sequence, one of ordinary skill in the art can screen compound libraries for compounds which are capable of specifically binding this determinant and thus capable of preventing toxin-antitoxin binding.

An agent which specifically binds to the antitoxin binding determinant can be, for example, a peptide, a polynucleotide, a carbohydrate, a small organic molecule, or a non-biological compound.

The phrase "non-biological compound" used herein refers to an organic or an inorganic compound which is not naturally present in living organisms.

A peptide which specifically binds to the antitoxin binding determinant itself can be a toxin derivative which includes the toxin binding determinant sequence (the portion of the toxin molecule which participates the antitoxin-toxin binding). In cases where the antitoxin binding determinant is isolated, the toxin binding determinant sequence can be readily identified using, for example, the peptide array

analysis procedure described in Example 6 (by using toxin derivative peptides to form the array and a labeled antitoxin derivative as a probe).

Alternatively, a peptide, a polynucleotide, a carbohydrate, a small organic molecule, or a non-biological compound which specifically binds to the antitoxin binding determinant can be identified by using standard rational drug design methods or high throughput screening of combinatorial libraries, as described hereinbelow.

Disrupting binding between members of a toxin-antitoxin pair may also be effected by providing to the subject an agent (e.g., peptide) which specifically binds the toxin in a manner which interrupts toxin-antitoxin binding while at the same time does not substantially affect toxin activity. Toxin sequence regions (toxin binding determinants) which can be targeted by such an agent and agents which specifically bind thereto can be identified using methodology similar to that described above with respect to identifying antitoxin binding determinant sequences and agents which specifically bind thereto.

The agent identified capable of binding to the antitoxin or toxin binding determinant of infectious bacteria can be administered to the subject in need orally, intravenously, intraperitoneally, intramuscularly, subcutaneously, intracavity, or transdermally. A peptide or polynucleotide agent is preferably administered encapsulated in a suitable carrier, such as a liposome. Suitable encapsulated carriers may be prepared using methods such as described, for example, in U.S. Pat. No. 6,610,478, 6,309,669, 5,013,556 and 4,925,673 and by Clarenc *et al.* Anti-Cancer Drug Design, 8:81-94, 1993; Felgner, Advanced Drug Delivery Reviews, 5:163-187, 1990; and Wang *et al.*, Biochem. 28:9508-9514, 1989.

Delivery of a polynucleotide agent to target infecting bacteria may also be effected by utilizing a recombinant nonlytic phage, such as M13 (Westwater *et al.*, Antimicrobial Agents and Chemotherapy 47: 1301-1307, 2003).

Delivery of carbohydrates, small organic molecules, or non-biological compounds to target infecting bacteria in the subject may be effected using methods well known in the art such as described, for example, by Johnson *et al.*, eds. (Drug Delivery Systems, Chichester, England: Ellis Horwood Ltd., 1987). Additional

methods of formulating and administering pharmaceutical compositions are described hereinbelow.

Another agent which can be used to specifically inhibit toxin-antitoxin binding is an antibody or an antibody fragment.

5 Preferably, the antibody or antibody fragment specifically binds at least one epitope of the antitoxin binding determinant. As used herein, the term "epitope" refers to any antigenic determinant on an antigen to which the paratope of an antibody binds.

Epitopic determinants usually consist of chemically active surface groupings  
10 of molecules such as amino acids or carbohydrate side chains and usually have specific three dimensional structural characteristics, as well as specific charge characteristics.

The phrase "antibody or an antibody fragment" as used in this invention includes intact molecules as well as functional fragments thereof, such as Fab,  
15 F(ab')<sub>2</sub>, and Fv that are capable of binding to macrophages. These functional antibody fragments are defined as follows: (1) Fab, the fragment which contains a monovalent antigen-binding fragment of an antibody molecule, can be produced by digestion of whole antibody with the enzyme papain to yield an intact light chain and a portion of one heavy chain; (2) Fab', the fragment of an antibody molecule that can  
20 be obtained by treating whole antibody with pepsin, followed by reduction, to yield an intact light chain and a portion of the heavy chain; two Fab' fragments are obtained per antibody molecule; (3) F(ab')<sub>2</sub>, the fragment of the antibody that can be obtained by treating whole antibody with the enzyme pepsin without subsequent reduction; F(ab')<sub>2</sub> is a dimer of two Fab' fragments held together by two disulfide  
25 bonds; (4) Fv, defined as a genetically engineered fragment containing the variable region of the light chain and the variable region of the heavy chain expressed as two chains; and (5) Single chain antibody ("SCA"), a genetically engineered molecule containing the variable region of the light chain and the variable region of the heavy chain, linked by a suitable polypeptide linker as a genetically fused single chain  
30 molecule.

Methods of producing polyclonal and monoclonal antibodies as well as fragments thereof are well known in the art (see for example, Harlow and Lane,

Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory, New York, 1988).

Antibody fragments according to the present invention can be prepared by proteolytic hydrolysis of the antibody or by expression in *E. coli* or mammalian cells (e.g. Chinese hamster ovary cell culture or other protein expression systems) of DNA encoding the fragment. Antibody fragments can be obtained by pepsin or papain digestion of whole antibodies by conventional methods. For example, antibody fragments can be produced by enzymatic cleavage of antibodies with pepsin to provide a 5S fragment denoted F(ab')<sub>2</sub>. This fragment can be further cleaved using a thiol reducing agent, and optionally a blocking group for the sulfhydryl groups resulting from cleavage of disulfide linkages, to produce 3.5S Fab' monovalent fragments. Alternatively, an enzymatic cleavage using pepsin produces two monovalent Fab' fragments and an Fc fragment directly. These methods are described, for example, in U.S. Pat. Nos. 4,036,945 and 4,331,647, and references contained therein, which patents are hereby incorporated by reference in their entirety. See also Porter, R. R. (Biochem. J. 73: 119-126, 1959). Other methods of cleaving antibodies, such as separation of heavy chains to form monovalent light-heavy chain fragments, further cleavage of fragments, or other enzymatic, chemical, or genetic techniques may also be used, so long as the fragments bind to the antigen that is recognized by the intact antibody.

Fv fragments comprise an association of VH and VL chains. This association may be noncovalent, as described in Inbar *et al.* (Proc. Natl Acad. Sci. USA 69:2659-2662, 1972). Alternatively, the variable chains can be linked by an intermolecular disulfide bond or cross-linked by chemicals such as glutaraldehyde.

Preferably, the Fv fragments comprise VH and VL chains connected by a peptide linker. These single-chain antigen binding proteins (scFv) are prepared by constructing a structural gene comprising DNA sequences encoding the VH and VL domains connected by an oligonucleotide. The structural gene is inserted into an expression vector, which is subsequently introduced into a host cell such as *E. coli*. The recombinant host cells synthesize a single polypeptide chain with a linker peptide bridging the two V domains. Methods for producing scFv are described, for example, by Whitlow and Filpula (Methods 2: 97-105, 1991), Bird *et al.* (Science

242:423-426, 1988), Pack *et al.* (Bio/Technology 11:1271-1277, 1993) and in U.S. Pat. No. 4,946,778.

Another form of an antibody fragment is a peptide coding for a single complementarity-determining region (CDR). CDR peptides ("minimal recognition  
5 units") can be obtained by constructing genes encoding the CDR of an antibody of interest. Such genes are prepared, for example, by using the polymerase chain reaction to synthesize the variable region from RNA of antibody-producing cells. See, for example, Larrick and Fry (Methods, 2: 106-110, 1991).

Humanized forms of non-human (e.g., murine) antibodies are chimeric  
10 molecules of immunoglobulins, immunoglobulin chains or fragments thereof (such as Fv, Fab, Fab', F(ab')<sub>2</sub> or other antigen-binding subsequences of antibodies) which contain minimal sequence derived from non-human immunoglobulin. Humanized antibodies include human immunoglobulins (recipient antibody) in which residues form a complementary determining region (CDR) of the recipient are replaced by  
15 residues from a CDR of a non-human species (donor antibody) such as mouse, rat or rabbit having the desired specificity, affinity and capacity. In some instances, Fv framework residues of the human immunoglobulin are replaced by corresponding non-human residues. Humanized antibodies may also comprise residues which are found neither in the recipient antibody nor in the imported CDR or framework  
20 sequences. In general, the humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the CDR regions correspond to those of a non-human immunoglobulin and all or substantially all of the FR regions are those of a human immunoglobulin consensus sequence. The humanized antibody optimally also will comprise at least a portion of  
25 an immunoglobulin constant region (Fc), typically that of a human immunoglobulin (Jones *et al.*, Nature, 321:522-525, 1986; Riechmann *et al.*, Nature, 332:323-329, 1988; and Presta, Curr. Op. Struct. Biol., 2:593-596, 1992).

Methods for humanizing non-human antibodies or antibody fragments are well known in the art. Generally, a humanized antibody has one or more amino acid  
30 residues introduced into it from a source which is non-human. These non-human amino acid residues are often referred to as import residues, which are typically taken from an import variable domain. Humanization can be essentially performed



following the method of Jones *et al.* (Nature, 321:522-525, 1986), Riechmann *et al.* (Nature 332:323-327, 1988), and Verhoeyen *et al.* (Science, 239:1534-1536, 1988), by substituting rodent CDRs or CDR sequences for the corresponding sequences of a human antibody. Accordingly, such humanized antibodies are chimeric antibodies  
5 (U.S. Pat. No. 4,816,567), wherein substantially less than an intact human variable domain has been substituted by the corresponding sequence from a non-human species. In practice, humanized antibodies are typically human antibodies in which some CDR residues and possibly some FR residues are substituted by residues from analogous sites in rodent antibodies.

10 Human antibodies or antibody fragments can also be produced using various techniques known in the art, including phage display libraries (Hoogenboom and Winter, J. Mol. Biol., 227:381, 1991; Marks *et al.*, J. Mol. Biol., 222:581, 1991). The techniques of Cole *et al.* and Boerner *et al.* are also available for the preparation of human monoclonal antibodies (Cole *et al.*, Monoclonal Antibodies and Cancer  
15 Therapy, Alan R. Liss, p. 77 (1985) and Boerner *et al.*, J. Immunol., 147(1):86-95 (1991)]. Similarly, human antibodies can be made by introduction of human immunoglobulin loci into transgenic animals, e.g., mice in which the endogenous immunoglobulin genes have been partially or completely inactivated. Upon challenge, human antibody production is observed, which closely resembles that seen in humans  
20 in all respects, including gene rearrangement, assembly, and antibody repertoire. This approach is described, for example, in U.S. Pat. Nos. 5,545,807; 5,545,806; 5,569,825; 5,625,126; 5,633,425; 5,661,016, and in the following scientific publications: Marks *et al.*, Bio/Technology 10: 779-783 (1992); Lonberg *et al.*, Nature 368: 856-859 (1994); Morrison, Nature 368 812-13 (1994); Fishwild *et al.*,  
25 Nature Biotechnology 14, 845-51 (1996); Neuberger, Nature Biotechnology 14: 826 (1996); and Lonberg and Huszar, Intern. Rev. Immunol. 13, 65-93 (1995).

The antibody or antibody fragment of the present invention can be delivered to the target infecting bacteria in the subject using methods known in the art. Preferably, the antibody or antibody fragment is administered contained in a  
30 microparticle or microencapsulated carrier such as described, for example, in U.S. Pat. Nos. 6,610,478, 6,309,669, 5,013,556 and 4,925,673 and by Clarenc *et al.* Anti-

Cancer Drug Design, 8:81-94, 1993; Felgner, Advanced Drug Delivery Reviews, 5:163-187, 1990; and Wang *et al.*, Biochem. 28:9508-9514, 1989.

Preventing or disrupting binding of a toxin-antitoxin pair may also be effected by providing to the subject an antisense polynucleotide capable of specifically hybridizing with an mRNA transcript encoding the antitoxin.

Design of antisense molecules which can be used to efficiently hybridize with an mRNA transcript encoding the antitoxin must be effected while considering two aspects important to the antisense approach. The first aspect is delivery of the oligonucleotide into the cytoplasm of the appropriate cells, while the second aspect is design of an oligonucleotide which specifically binds the designated mRNA within cells in a way which inhibits translation thereof.

The prior art teaches of a number of delivery strategies which can be used to efficiently deliver oligonucleotides into a wide variety of cell types [see, for example, Luft J Mol Med 76: 75-6 (1998); Kronenwett *et al.* Blood 91: 852-62 (1998); Rajur *et al.* Bioconj Chem 8: 935-40 (1997); Lavigne *et al.* Biochem Biophys Res Commun 237: 566-71 (1997) and Aoki *et al.* (1997) Biochem Biophys Res Commun 231: 540-5 (1997)].

In addition, algorithms for identifying those sequences with the highest predicted binding affinity for their target mRNA based on a thermodynamic cycle that accounts for the energetics of structural alterations in both the target mRNA and the oligonucleotide are also available [see, for example, Walton *et al.* Biotechnol Bioeng 65: 1-9 (1999)].

Such algorithms have been successfully used to implement an antisense approach in cells. For example, the algorithm developed by Walton *et al.* enabled scientists to successfully design antisense oligonucleotides for rabbit beta-globin (RBG) and mouse tumor necrosis factor-alpha (TNF alpha) transcripts. The same research group has more recently reported that the antisense activity of rationally selected oligonucleotides against three model target mRNAs (human lactate dehydrogenase A and B and rat gp130) in cell culture as evaluated by a kinetic PCR technique proved effective in almost all cases, including tests against three different targets in two cell types with phosphodiester and phosphorothioate oligonucleotide chemistries.

In addition, several approaches for designing and predicting efficiency of specific oligonucleotides using an *in vitro* system were also published (Matveeva *et al.*, Nature Biotechnology 16: 1374 - 1375 (1998)).

Several clinical trials have demonstrated safety, feasibility and activity of antisense oligonucleotides. For example, antisense oligonucleotides suitable for the treatment of cancer have been successfully used [Holmund *et al.*, Curr Opin Mol Ther 1:372-85 (1999)], while treatment of hematological malignancies via antisense oligonucleotides targeting c-myc gene, p53 and Bcl-2 had entered clinical trials and had been shown to be tolerated by patients [Gerwitz Curr Opin Mol Ther 1:297-306 (1999)].

An example of using antisense molecules to treat bacterial infection is described in U.S. Pat. No. 6,677,153. Accordingly, oligomers antisense to bacterial 16S or 23S rRNA are capable of selectively modulating the biological activity thereof and thus can be used as antibacterial agents.

Thus, the current consensus is that recent developments in the field of antisense technology which, as described above, have led to the generation of highly accurate antisense design algorithms and a wide variety of oligonucleotide delivery systems, enable an ordinarily skilled artisan to design and implement antisense approaches suitable for downregulating expression of known sequences without having to resort to undue trial and error experimentation. A suitable antisense sequence according to the teaching of the present invention can be, for example, the antisense to YefM antitoxin set forth in SEQ ID NO: 126.

Preventing or disrupting binding of a toxin-antitoxin pair may also be effected by providing a small interfering RNA (siRNA) molecule which specifically cleaves the antitoxin transcripts.

RNA interference is a two step process. The first step, which is termed as the initiation step, input dsRNA is digested into 21-23 nucleotide (nt) small interfering RNAs (siRNA), probably by the action of Dicer, a member of the RNase III family of dsRNA-specific ribonucleases, which processes (cleaves) dsRNA (introduced directly or via a transgene or a virus) in an ATP-dependent manner. Successive cleavage events degrade the RNA to 19-21 bp duplexes (siRNA); each with 2-

nucleotide 3' overhangs [Hutvagner and Zamore Curr. Opin. Genetics and Development 12:225-232 (2002); and Bernstein Nature 409:363-366 (2001)].

In the effector step, the siRNA duplexes bind to a nuclease complex to form the RNA-induced silencing complex (RISC). An ATP-dependent unwinding of the siRNA duplex is required for activation of the RISC. The active RISC then targets the homologous transcript by base pairing interactions and cleaves the mRNA into 12 nucleotide fragments from the 3' terminus of the siRNA [Hutvagner and Zamore Curr. Opin. Genetics and Development 12:225-232 (2002); Hammond et al. (2001) Nat. Rev. Gen. 2:110-119 (2001); and Sharp Genes. Dev. 15:485-90 (2001)]. Although the mechanism of cleavage is still to be elucidated, research indicates that each RISC contains a single siRNA and an RNase [Hutvagner and Zamore Curr. Opin. Genetics and Development 12:225-232 (2002)].

Because of the remarkable potency of RNAi, an amplification step within the RNAi pathway has been suggested. Amplification could occur by copying of the input dsRNAs which would generate more siRNAs, or by replication of the siRNAs formed. Alternatively or additionally, amplification could be effected by multiple turnover events of the RISC [Hammond et al. Nat. Rev. Gen. 2:110-119 (2001), Sharp Genes. Dev. 15:485-90 (2001); Hutvagner and Zamore Curr. Opin. Genetics and Development 12:225-232 (2002)]. For more information on RNAi see the following reviews Tuschl ChemBiochem. 2:239-245 (2001); Cullen Nat. Immunol. 3:597-599 (2002); and Brantl Biochem. Biophys. Act. 1575:15-25 (2002).

Synthesis of RNAi molecules suitable for use with the present invention can be effected as follows. First, the target antitoxin mRNA sequence is scanned downstream of the AUG start codon for AA dinucleotide sequences. Occurrence of each AA and the 3' adjacent 19 nucleotides is recorded as potential siRNA target sites. Preferably, siRNA target sites are selected from the open reading frame, as untranslated regions (UTRs) are richer in regulatory protein binding sites. UTR-binding proteins and/or translation initiation complexes may interfere with binding of the siRNA endonuclease complex [Tuschl ChemBiochem. 2:239-245]. It will be appreciated though, that siRNAs directed at untranslated regions may also be effective, as demonstrated for GAPDH wherein siRNA directed at the 5' UTR

mediated about 90 % decrease in cellular GAPDH mRNA and completely abolished protein level ([www.ambion.com/techlib/tn/91/912.html](http://www.ambion.com/techlib/tn/91/912.html)).

Second, potential target sites are compared to an appropriate genomic database (e.g., human, mouse, rat etc.) using any sequence alignment software, such as the BLAST software available from the NCBI server (www.ncbi.nlm.nih.gov/BLAST/). Putative target sites which exhibit significant homology to other coding sequences are filtered out.

Qualifying target sequences are selected as template for siRNA synthesis. Preferred sequences are those including low G/C content as these have proven to be more effective in mediating gene silencing as compared to those with G/C content higher than 55 %. Several target sites are preferably selected along the length of the target gene for evaluation. For better evaluation of the selected siRNAs, a negative control is preferably used in conjunction. Negative control siRNA preferably include the same nucleotide composition as the siRNAs but lack significant homology to the genome. Thus, a scrambled nucleotide sequence of the siRNA is preferably used, provided it does not display any significant homology to any other gene. Suitable siRNA molecules according to the teaching of the preset invention include, for example, the siRNA to the YefM antitoxin set forth in SEQ ID NOs: 127-128.

Preventing or disrupting binding of a toxin-antitoxin pair may also be effected by providing a DNAzyme molecule capable of specifically cleaving an mRNA transcript or DNA sequence of the antitoxin. DNAzymes are single-stranded polynucleotides which are capable of cleaving both single and double-stranded target sequences (Breaker, R.R. and Joyce, G. Chemistry and Biology 1995;2:655; Santoro, S.W. & Joyce, G.F. Proc. Natl. Acad. Sci. USA 1997;94:4262). A general model (the "10-23" model) for the DNAzyme has been proposed. "10-23" DNAzymes have a catalytic domain of 15 deoxyribonucleotides, flanked by two substrate-recognition domains of seven to nine deoxyribonucleotides each. This type of DNAzyme can effectively cleave its substrate RNA at purine:pyrimidine junctions (Santoro, S.W. & Joyce, G.F. Proc. Natl. Acad. Sci. USA 1999; for rev of DNAzymes see Khachigian, LM [Curr Opin Mol Ther 4:119-21 (2002)]).

Examples of construction and amplification of synthetic, engineered DNAzymes recognizing single and double-stranded target cleavage sites have been

disclosed in U.S. Pat. No. 6,326,174 to Joyce *et al.* DNazymes of similar design directed against the human Urokinase receptor were recently observed to inhibit Urokinase receptor expression, and successfully inhibit colon cancer cell metastasis in vivo (Itoh *et al.*, 20002, Abstract 409, Ann Meeting Am Soc Gen Ther  
5 [www.asgt.org](http://www.asgt.org)). In another application, DNazymes complementary to bcr-abl oncogenes were successful in inhibiting the oncogenes expression in leukemia cells, and lessening relapse rates in autologous bone marrow transplant in cases of CML and ALL.

Preventing or disrupting binding of a toxin-antitoxin pair may also be effected  
10 by providing a ribozyme which specifically cleaves transcripts encoding the antitoxin

Ribozymes are being increasingly used for the sequence-specific inhibition of gene expression by the cleavage of mRNAs encoding polypeptides of interest [Welch *et al.*, Curr Opin Biotechnol. 9:486-96 (1998)]. The possibility of designing ribozymes to cleave any specific target RNA has rendered them valuable tools in  
15 both basic research and therapeutic applications. In the therapeutics area, ribozymes have been exploited to target viral RNAs in infectious diseases, dominant oncogenes in cancers and specific somatic mutations in genetic disorders [Welch *et al.*, Clin Diagn Virol. 10:163-71 (1998)]. Most notably, several ribozyme gene therapy protocols for HIV patients are already in Phase 1 trials. More recently, ribozymes  
20 have been used for transgenic animal research, gene target validation and pathway elucidation. Several ribozymes are in various stages of clinical trials. ANGIOZYME was the first chemically synthesized ribozyme to be studied in human clinical trials. ANGIOZYME specifically inhibits formation of the VEGF-r (Vascular Endothelial Growth Factor receptor), a key component in the angiogenesis  
25 pathway. Ribozyme Pharmaceuticals, Inc., as well as other firms has demonstrated the importance of anti-angiogenesis therapeutics in animal models. HEPTAZYME, a ribozyme designed to selectively destroy Hepatitis C Virus (HCV) RNA, was found effective in decreasing Hepatitis C viral RNA in cell culture assays (Ribozyme Pharmaceuticals, Incorporated - WEB home page).

30 Essentially, binding of any toxin-antitoxin pair of any bacterium can be prevented or disrupted using the above described agents and methodology. Table 1

below provides examples of several toxin-antitoxin pairs which can be targeted by the present invention.

**Table 1**  
**Target bacterial toxin-antitoxin pairs**

Bacterial species or strain *	Antitoxin		Toxin	
	Amino-acid SEQ ID NO	Polynucleotide SEQ ID NO	Amino-acid SEQ ID NO	Polynucleotide SEQ ID NO
<i>Actinobacillus actinomycetemcomitans</i>	68	10	69	11
<i>Agrobacterium tumefaciens</i>	70	12	71	13
<i>Burkholderia cepacia</i>	72	14	73	15
<i>Coxiella burnetii</i>	74	16	75	17
<i>Escherichia coli</i> (YefM/YoeB)	76	18	77	19
<i>Enterococcus faecium</i> pRUM plasmid	78	20	79	21
<i>Francisella tularensis</i> pFNL10 plasmid (Phd)	80	22	81	23
<i>Klebsiella pneumoniae</i>	82	24	83	25
<i>Mycobacterium bovis</i>	84	26	85	27
<i>Mycobacterium tuberculosis</i>	86	28	87	29
<i>Neisseria europaea</i> A	88	30	89	31
<i>Neisseria europaea</i> B	90	32	91	33
<i>Neisseria europaea</i> C	92	34	93	35
<i>Nostoc</i> sp. PCC 7120	94	36	95	37
<i>Pseudomonas fluorescence</i>	96	38	97	39
<i>Pseudomonas putida</i>	98	40	99	41
<i>Pseudomonas syringae</i>	100	42	101	43
<i>Rickettsia conorii</i>	102	44	103	45
<i>Salmonella typhimarium</i>	104	46	105	47
<i>Streptococcus aureus</i>	106	48	107	49
<i>Streptococcus pneumoniae</i>	108	50	109	51
<i>Streptomyces coelicolor</i>	110	52	111	53
<i>Streptomyces viridochromogenes</i>	112	54	113	55
<i>Synechocystis</i> sp. PCC 7942	114	56	115	57
<i>Synechocystis</i> sp. PCC 6803 A	116	58	117	59
<i>Synechocystis</i> sp. PCC 6803 B	118	60	119	61
<i>Tiobacillus ferrooxidans</i>	120	62	121	63
<i>Yersinia enterocolitica</i> A	122	64	123	65
<i>Yersinia enterocolitica</i> B	124	66	125	67

5 \* species which appear in bold are major human pathogens

As is mentioned hereinabove, an agent which specifically binds to the antitoxin binding determinant, such as a peptide or a non-biological compound can be identified using rational drug design methods, following guidance such as described, for example, by Halperin *et al.*, Proteins 47: 409–43, 2002; Gohlke and Klebe Curr Opin Struct Biol. 11: 231–235, 2001; Zeng J., Comb Chem High Throughput Screen. 3: 355–62, 2000; and RACHEL: Theory of drug design, [http://www.newdrugdesign.com/Rachel\\_Theory.htm#Software](http://www.newdrugdesign.com/Rachel_Theory.htm#Software)). 3D chemical structure databases can be screened by using a suitable software such as, for example, ISIS (MDL Information Systems, San Leandro, <http://www.molinfo.com>), MACCS-3D (Martin, Y. C., J. Med. Chem. 35, 2145–2154, 1992), The Cambridge Structural Database (CSD; <http://www.ccdc.cam.ac.uk/prods/csd/csd.html>), Fine Chemical Database (reviewed in Rusinko A., 1993. Chem Des Auto. News 8, 44–47), and the NCBI's Molecular Modeling DataBase: MMDB; <http://www.ncbi.nlm.nih.gov/Structure/MMDB/mmdb.shtml>.

Alternatively, an agent which specifically binds to the antitoxin binding determinant (herein refers to as the “target sequence”), such as a peptide, a polynucleotide, a carbohydrate, or a non-biological compound can be identified by high throughput screening of combinatorial libraries.

The term “library” used herein refers to a collection of chemical or biological entities which can be screened simultaneously for a property of interest.

The phrase “combinatorial library” used herein refers to a library in which the individual members are either systematic or random combinations of a limited set of basic elements, the properties of each member being dependent on the choice and location of the elements incorporated into it.

A peptide library may be prepared by either biological or non-biological synthesis methods. In a biological synthesis method, a gene encoding the peptides of interest is expressed in a host cell such that the peptides are displayed either on the surface of the cell or on the outer coat of phage produced by the cell. For example, a phage libraries can be constructed according to the protocols (Construction of Random Peptide Libraries in Bacteriophage M13 in Phage Display of Peptides and Proteins: A Laboratory Manual. Edited by B. Kay, J. Winter and J. McCafferty. Academic Press 1996.).



In order to achieve diversity, the gene must be randomized at those codons corresponding to variable residues of the peptide. It thus is not a single DNA, but rather a DNA mixture, which is introduced into the host cell culture, so that each cell has the potential, depending on which DNA it receives, of expressing any of the many possible peptide sequences of the library. The gene may be randomized by using a mixture of nucleotides rather than a pure nucleotide during appropriate synthetic cycles. The synthesis cycles may add one base at a time, or an entire codon. Examples of suitable procedures for constructing libraries of peptides generated by gene expression are described in Marks *et al.*, J Mol Biol, 222:581-597, 1991; Lam *et al.*, Nature, 354:82-84, 1991; Colas *et al.*, Nature, 380:548-550, 1996; Lu, Bio/Technology, 13:366-372, 1990; and Smith, Science, 228:1315-1317, 1985.

The peptide library may also be prepared nonbiologically by stepwise addition of amino acids. During the cycles which incorporate variable residues, the activated amino acid is chosen randomly from an amino acid mixture. Preferably, the synthesis is carried out on a solid surface, such as a pin or bead (Geyesen *et al.*, Proc Natl Acad Sci USA 81: 3998-4002, 1984), or bead (Lam *et al.*, Nature 354: 82-84, 1991).

The peptide library may be attached to a polysome using a procedure such as described, for example, in U.S. Pat. Nos. 5,643,768 and 5,658,754; Gersuk, *et al.*, Biochem. Biophys. Res. Comm. 232:578, 1997; and Mattheakis *et al.*, Proc. Nat. Acad. Sci. USA, 91:9022-9026, 1994.

If the peptide library is on a solid phase, then preferably the target sequence is tagged. Suitable tags includes, but not limited to, enzymes such as  $\beta$ -galactosidase, luciferase, or glutathione-S-transferase (GST) and green fluorescent protein (GFP). Other tags can be incorporated via recombinant techniques include substrate sites for enzymes such as protein kinase A which allows for the rapid and efficient labeling of the target sequence with  $^{32}\text{P}$ . Less desirable, but still feasible, is the radio labeling of the recombinant protein, e.g., in vivo with  $^{14}\text{C}$  or  $^3\text{H}$  labeled amino acids or *in vitro* with  $^{125}\text{I}$ .

If the peptide library is in solution, the target sequence may be immobilized on chromatographic media either directly [e.g., by using AFFIGEL matrix

(BioRad)], or indirectly. In indirect immobilization, the target sequence is noncovalently conjugated to the support by using an affinity reagent. For example, histidine-tagged target sequence may be immobilized on QIAGEN nickel binding resin, or a GST -tagged target sequence may be immobilized on glutathione SEPHAROSE chromatography matrix (Pharmacia). Subsequently, the immobilized target sequence is used to separate out peptides with desired activity by using methods such as described, for example, by Cantley *et al.* Trends Biochem. Sci. 20: 470-475, 1995; and Zhou and Cantley, Methods Enzymol 254: 523-535, 1995; Zhou and Cantley, Cell 72: 767-778, 1993.

10 In screening phage libraries, the target sequence is preferably immobilized on a solid support and screened using a procedure such as described, for example, by Devlin *et al.* (Science 249: 404-406, 1990) and Scott and Smith (Gene 128: 59-65, 1993).

Additionally, or alternatively to peptides, the agent which specifically binds to the target sequence can be a polynucleotide (aptamer). Target sequence- binding aptamers can be isolated using screening methods such as described, for example, in U.S. Pat. Nos. 5,270,163; 5,475,096; 5,567,588; 5,595,877; 5,637,459; 5,683,867; and 5,705,337 and by Colas *et al.* (Nature 380: 548-550, 1996) and Ellington and Szobtak (Nature 246: 818, 1990). For example, the starting libraries for a DNA library may be defined sequences on each end of 10 to 30 bases flanking a random core of 10 to 100 bases. Primers complementary to the defined sequences on each end are used to amplify the library and one would have a tag (such as biotin). Following amplification, the double stranded DNA is bound to a matrix (streptavidin agarose) and denatured to release ssDNA. To isolate the ligand, the target sequence is incubated with a starting library of single stranded DNA (ssDNA) and the aptamers are allowed to bind. Target-sequence and aptamer complexes are then bound onto nitrocellulose or nylon membranes and the unbound ssDNA molecules are discarded. The aptamers bound onto the target sequence are then eluted by one of several methods well known in the art (e.g., pH shock, phenol extraction, SDS treatment or heat), precipitated with ethanol and then preferably amplified by PCR to synthesize a new pool for an additional round of selection.

This process is preferably repeated 1 to 20 times. The number of repetitions

is determined by monitoring the enrichment for binders after each round or after every other round of selection. This could be accomplished in several ways. The most often used approach is to radioactively label a small percentage of the library and monitor the fraction of the library retained on the filter after each round. An  
5 alternative method is to use a primer in the amplification reaction which would allow the aptamer to be detected. Two examples of this are rhodamine and digoxigenin. Rhodamine is detected directly by fluorescence and DIG is detected by an antibody which is either directly or indirectly coupled to an enzymatic or fluorescence readout. Using a labeled primer would allow the detection of aptamer binding to  
10 target in a standard ELISA format in which the target sequence is immobilized in the well of a plate, the aptamer is added and allowed to bind and is then detected using one of the methods mentioned hereinabove. Once a sufficient level of enrichment has been attained, the final pool is amplified and cloned into a plasmid which allows for the rapid sequencing of the inserts.

15 Additionally, or alternatively to peptides and polynucleotides, the agent which specifically binds to the target sequence can be a carbohydrate or a small organic molecule. Libraries of carbohydrates and small organic molecules may be prepared and screened for target sequence binding activity using methods such as described, for example, by Eichler et al. (Med Res Rev. 15:481-96, 1995).

20 Additionally, or alternatively the agent which specifically binds to the target sequence can be a non-biological compound. Libraries of non-biological compounds may be generated and screened for target sequence binding activity using methods such as described in details in U.S. Pat. No. 6,617,114.

Agents identified capable of preventing or disrupting binding of toxin-  
25 antitoxin pairs in bacterial cells can be evaluated *in vitro* for their capacity to induce death in bacteria expressing the toxin-antitoxin pairs.

Thus, according to another aspect of the present invention, there is provided a method of identifying a molecule capable of inducing death of a bacterial cell. The method includes exposing toxin and antitoxin polypeptides of a toxin-antitoxin pair  
30 produced by the bacterial cell to a plurality of molecules followed by identifying a molecule which is capable of preventing or disrupting binding between the antitoxin and the toxin polypeptides, thereby identifying the molecule capable of inducing

death of the bacterial cell.

Preferably, exposing is effected by administering the plurality of molecules to bacteria expressing the toxin and antitoxin polypeptides, followed by determining growth of the bacteria exposed to the plurality of molecules and selecting at least one  
5 of the bacteria exhibiting a reduction in growth as compared with similar bacteria not exposed to the plurality of molecules. Preferably, the bacteria are genetically modified and cultured to overexpress the toxin-antitoxin pair, using a procedure such as described, for example, in Example 3 of the Examples section hereinbelow.

An agent identified capable of preventing or disrupting binding of toxin-  
10 antitoxin pairs in bacteria, can be used in therapy *per se* or as part (active ingredient) of a pharmaceutical composition.

As used herein a "pharmaceutical composition" refers to a preparation of one or more of the active ingredients described herein with other chemical components such as physiologically suitable carriers and excipients. The purpose  
15 of a pharmaceutical composition is to facilitate administration of a compound to an organism.

Hereinafter, the phrases "physiologically acceptable carrier" and "pharmaceutically acceptable carrier" which may be interchangeably used refer to a carrier or a diluent that does not cause significant irritation to an organism and does  
20 not abrogate the biological activity and properties of the administered compound. An adjuvant is included under these phrases.

Herein the term "excipient" refers to an inert substance added to a pharmaceutical composition to further facilitate administration of an active ingredient. Examples, without limitation, of excipients include calcium carbonate,  
25 calcium phosphate, various sugars and types of starch, cellulose derivatives, gelatin, vegetable oils and polyethylene glycols.

Techniques for formulation and administration of drugs may be found in "Remington's Pharmaceutical Sciences," Mack Publishing Co., Easton, PA, latest edition, which is incorporated herein by reference.

Suitable routes of administration may, for example, include oral, rectal,  
30 transmucosal, especially transnasal, intestinal or parenteral delivery, including intramuscular, subcutaneous and intramedullary injections as well as intrathecal,

direct intraventricular, intravenous, intraperitoneal, intranasal, or intraocular injections.

Alternately, one may administer the pharmaceutical composition in a local rather than systemic manner, for example, via injection of the pharmaceutical composition directly into a bone tissue region of a patient.

Pharmaceutical compositions of the present invention may be manufactured by processes well known in the art, e.g., by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping or lyophilizing processes.

Pharmaceutical compositions for use in accordance with the present invention thus may be formulated in conventional manner using one or more physiologically acceptable carriers comprising excipients and auxiliaries, which facilitate processing of the active ingredients into preparations which can be used pharmaceutically. Proper formulation is dependent upon the route of administration chosen.

For injection, the active ingredients of the pharmaceutical composition may be formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hank's solution, Ringer's solution, or physiological salt buffer. One route of administration which is suited for the pharmaceutical compositions of the present invention is sub-periosteal injection, as described in U.S. Pat. No. 6,525,030 to Eriksson. For transmucosal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art.

For oral administration, the pharmaceutical composition can be formulated readily by combining the active compounds with pharmaceutically acceptable carriers well known in the art. Such carriers enable the pharmaceutical composition to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions, and the like, for oral ingestion by a patient. Pharmacological preparations for oral use can be made using a solid excipient, optionally grinding the resulting mixture, and processing the mixture of granules, after adding suitable auxiliaries if desired, to obtain tablets or dragee cores. Suitable excipients are, in particular, fillers such as sugars, including lactose,

sucrose, mannitol, or sorbitol; cellulose preparations such as, for example, maize starch, wheat starch, rice starch, potato starch, gelatin, gum tragacanth, methyl cellulose, hydroxypropylmethyl-cellulose, sodium carbomethylcellulose; and/or physiologically acceptable polymers such as polyvinylpyrrolidone (PVP). If  
5 desired, disintegrating agents may be added, such as cross-linked polyvinyl pyrrolidone, agar, or alginic acid or a salt thereof such as sodium alginate. As used herein, the term "oral administration" includes administration of the pharmaceutical compound to any oral surface, including the tongue, gums, palate, or other buccal surfaces. Addition methods of oral administration include  
10 provision of the pharmaceutical composition in a mist, spray or suspension compatible with tissues of the oral surface.

Dragee cores are provided with suitable coatings. For this purpose, concentrated sugar solutions may be used which may optionally contain gum arabic, talc, polyvinyl pyrrolidone, carbopol gel, polyethylene glycol, titanium  
15 dioxide, lacquer solutions and suitable organic solvents or solvent mixtures. Dyestuffs or pigments may be added to the tablets or dragee coatings for identification or to characterize different combinations of active compound doses.

Pharmaceutical compositions which can be used orally, include push-fit capsules made of gelatin as well as soft, sealed capsules made of gelatin and a  
20 plasticizer, such as glycerol or sorbitol. The push-fit capsules may contain the active ingredients in admixture with filler such as lactose, binders such as starches, lubricants such as talc or magnesium stearate and, optionally, stabilizers. In soft capsules, the active ingredients may be dissolved or suspended in suitable liquids, such as fatty oils, liquid paraffin, or liquid polyethylene glycols. In addition,  
25 stabilizers may be added. All formulations for oral administration should be in dosages suitable for the chosen route of administration.

For buccal administration, the compositions may take the form of tablets or lozenges formulated in conventional manner.

For administration by nasal inhalation, the active ingredients for use  
30 according to the present invention are conveniently delivered in the form of an aerosol spray presentation from a pressurized pack or a nebulizer with the use of a suitable propellant, e.g., dichlorodifluoromethane, trichlorofluoromethane,

dichloro-tetrafluoroethane or carbon dioxide. In the case of a pressurized aerosol, the dosage unit may be determined by providing a valve to deliver a metered amount. Capsules and cartridges of, e.g., gelatin for use in a dispenser may be formulated containing a powder mix of the compound and a suitable powder base  
5 such as lactose or starch.

The pharmaceutical composition described herein may be formulated for parenteral administration, e.g., by bolus injection or continuous infusion. Formulations for injection may be presented in unit dosage form, e.g., in ampoules or in multidose containers with optionally, an added preservative. The  
10 compositions may be suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents.

Pharmaceutical compositions for parenteral administration include aqueous solutions of the active preparation in water-soluble form. Additionally,  
15 suspensions of the active ingredients may be prepared as appropriate oily or water based injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acids esters such as ethyl oleate, triglycerides or liposomes. Aqueous injection suspensions may contain substances, which increase the viscosity of the suspension, such as sodium carboxymethyl  
20 cellulose, sorbitol or dextran. Optionally, the suspension may also contain suitable stabilizers or agents which increase the solubility of the active ingredients to allow for the preparation of highly concentrated solutions.

Alternatively, the active ingredient may be in powder form for constitution with a suitable vehicle, e.g., sterile, pyrogen-free water based solution, before use.

25 The pharmaceutical composition of the present invention may also be formulated in rectal compositions such as suppositories or retention enemas, using, e.g., conventional suppository bases such as cocoa butter or other glycerides.

Pharmaceutical compositions suitable for use in context of the present invention include compositions wherein the active ingredients are contained in an  
30 amount effective to achieve the intended purpose. More specifically, a therapeutically effective amount means an amount of active ingredients (e.g. antisense oligonucleotide) effective to prevent, alleviate or ameliorate symptoms of

a disorder (e.g., mammary tumor progression) or prolong the survival of the subject being treated.

Determination of a therapeutically effective amount is well within the capability of those skilled in the art, especially in light of the detailed disclosure provided herein.

For any preparation used in the methods of the invention, the therapeutically effective amount or dose can be estimated initially from *in vitro* and cell culture assays. For example, a dose can be formulated in an animal model, such as the murine Neu model [Muller *et al.*, Cell 54, 105-115 (1988)], to achieve a desired concentration or titer.

Toxicity and therapeutic efficacy of the active ingredients described herein can be determined by standard pharmaceutical procedures *in vitro*, in cell cultures or experimental animals. The data obtained from these *in vitro* and cell culture assays and animal studies can be used in formulating a range of dosage for use in human. The dosage may vary depending upon the dosage form employed and the route of administration utilized. The exact formulation, route of administration and dosage can be chosen by the individual physician in view of the patient's condition. (See e.g., Fingl, *et al.*, 1975, in "The Pharmacological Basis of Therapeutics", Ch. 1 p.1).

Dosage amount and interval may be adjusted individually to levels of the active ingredient which are sufficient to, for example, retard tumor progression in the case of blastic metastases (minimal effective concentration, MEC). The MEC will vary for each preparation, but can be estimated from *in vitro* data. Dosages necessary to achieve the MEC will depend on individual characteristics and route of administration. Detection assays can be used to determine plasma concentrations.

Depending on the severity and responsiveness of the condition to be treated, dosing can be of a single or a plurality of administrations, with course of treatment lasting from several days to several weeks or diminution of the disease state is achieved.

The amount of a composition to be administered will, of course, be dependent on the subject being treated, the severity of the affliction, the manner of



administration, the judgment of the prescribing physician, etc.

Compositions of the present invention may, if desired, be presented in a pack or dispenser device, such as an FDA approved kit, which may contain one or more unit dosage forms containing the active ingredient. The pack may, for example, 5 comprise metal or plastic foil, such as a blister pack. The pack or dispenser device may be accompanied by instructions for administration. The pack or dispenser may also be accommodated by a notice associated with the container in a form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals, which notice is reflective of approval by the agency of the form of 10 the compositions or human or veterinary administration. Such notice, for example, may be of labeling approved by the U.S. Food and Drug Administration for prescription drugs or of an approved product insert. Compositions comprising a preparation of the invention formulated in a compatible pharmaceutical carrier may also be prepared, placed in an appropriate container, and labeled for treatment of an 15 indicated condition, as if further detailed above.

Hence, the present invention provides methods of identifying novel antibacterial agents capable of preventing or disrupting antitoxin-toxin binding in bacterial cells, pharmaceutical compositions comprising these agents and their use in treating bacterial infections.

20

Additional objects, advantages, and novel features of the present invention will become apparent to one ordinarily skilled in the art upon examination of the following examples, which are not intended to be limiting. Additionally, each of the various embodiments and aspects of the present invention as delineated 25 hereinabove and as claimed in the claims section below finds experimental support in the following examples.

### EXAMPLES

Reference is now made to the following examples, which together with the 30 above descriptions, illustrate the invention in a non limiting fashion.

Generally, the nomenclature used herein and the laboratory procedures utilized in the present invention include molecular, biochemical, microbiological

and recombinant DNA techniques. Such techniques are thoroughly explained in the literature. See, for example, "Molecular Cloning: A laboratory Manual" Sambrook et al., (1989); "Current Protocols in Molecular Biology" Volumes I-III Ausubel, R. M., ed. (1994); Ausubel et al., "Current Protocols in Molecular Biology", John Wiley and Sons, Baltimore, Maryland (1989); Perbal, "A Practical Guide to Molecular Cloning", John Wiley & Sons, New York (1988); Watson et al., "Recombinant DNA", Scientific American Books, New York; Birren et al. (eds) "Genome Analysis: A Laboratory Manual Series", Vols. 1-4, Cold Spring Harbor Laboratory Press, New York (1998); methodologies as set forth in U.S. Pat. Nos. 4,666,828; 4,683,202; 4,801,531; 5,192,659 and 5,272,057; "Cell Biology: A Laboratory Handbook", Volumes I-III Cellis, J. E., ed. (1994); "Current Protocols in Immunology" Volumes I-III Coligan J. E., ed. (1994); Stites et al. (eds), "Basic and Clinical Immunology" (8th Edition), Appleton & Lange, Norwalk, CT (1994); Mishell and Shiigi (eds), "Selected Methods in Cellular Immunology", W. H. Freeman and Co., New York (1980); available immunoassays are extensively described in the patent and scientific literature, see, for example, U.S. Pat. Nos. 3,791,932; 3,839,153; 3,850,752; 3,850,578; 3,853,987; 3,867,517; 3,879,262; 3,901,654; 3,935,074; 3,984,533; 3,996,345; 4,034,074; 4,098,876; 4,879,219; 5,011,771 and 5,281,521; "Oligonucleotide Synthesis" Gait, M. J., ed. (1984); "Nucleic Acid Hybridization" Hames, B. D., and Higgins S. J., eds. (1985); "Transcription and Translation" Hames, B. D., and Higgins S. J., eds. (1984); "Animal Cell Culture" Freshney, R. I., ed. (1986); "Immobilized Cells and Enzymes" IRL Press, (1986); "A Practical Guide to Molecular Cloning" Perbal, B., (1984) and "Methods in Enzymology" Vol. 1-317, Academic Press; "PCR Protocols: A Guide To Methods And Applications", Academic Press, San Diego, CA (1990); Marshak et al., "Strategies for Protein Purification and Characterization - A Laboratory Course Manual" CSHL Press (1996); all of which are incorporated by reference as if fully set forth herein. Other general references are provided throughout this document. The procedures therein are believed to be well known in the art and are provided for the convenience of the reader.

Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to

which this invention belongs. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, suitable methods and materials are described below.

5

### **EXAMPLE 1**

#### ***Identification of yefM and yoeB homologue genomic sequences in bacteria***

##### ***Materials and methods:***

Genomic sequences related to the *yefM* and *yoeB* genes of *E. coli* (SEQ ID NO: 18 and 19, respectively) were identified by a pair-constrained analysis using  
10 TBLASTN and PSI-BLAST searches (20) of non-redundant microbial genomes database at NCBI (<http://www.ncbi.nlm.nih.gov/BLAST/>). Putative *yefM* and *yoeB* homologue sequences were obtained and examined for constituting a toxin-antitoxin gene-pair module in the chromosome. Low homology unpaired sequences were discarded and pairs of genomic sequences positioned at distance of  
15 less than 100 bp were regarded as putative toxin-antitoxin systems.

##### ***Results:***

Genomic sequence pairs related to *yefM* and *yoeB* were identified in 29 bacterial strains representing 13 different genera and 25 different species (Figure 1). It is thereby demonstrated that toxin-antitoxin systems are common and widespread  
20 among bacteria and that such systems can be identified by using bioinformatical tools such as a pair-constrained analysis of genomic sequence databases.

### **EXAMPLE 2**

#### ***Sequence alignment of YefM and YoeB polypeptide homologues***

25

##### ***Materials and methods:***

Multiple alignments of translated sequences of the YefM and YoeB homologues identified in Example 1 above, were produced by CLASTAL W (21) with default settings and edited using JALVIEW editor.

##### ***Results:***

30

Alignments of the YoeB polypeptide homologues (Figure 2B) revealed a substantially higher level of homology than was observed within the YefM and Phd family of polypeptides (Figure 2A). The relatively high degree of conservation

within the YoeB homologues is well consistent with a toxic activity that explicitly targets a specific cellular determinants and that requires a well-defined fold such as a key-lock or induced fit recognition. On the other hand, the relatively low degree of conservation of YefM and Phd homologues is consistent with a polypeptide missing a clear structural recognition and/or catalytic activity that otherwise requires a defined configuration. It should be appreciated that YefM and Phd polypeptides could be irregularly conjugated to a Doc-like or YoeB-like toxins, two families of toxins that could not be aligned and do not share any substantial homology. It is, however, consistent with a family of polypeptides which is essentially designed to be recognized as a damaged polypeptide and does not represent an interactive or catalytic scaffold.

### EXAMPLE 3

#### *Characterizing YoeB and YefM polypeptides as a toxin-antitoxin pair*

##### *Materials and methods:*

*Cloning YefM, YoeB and YefM-YoeB encoding sequences into pBAD-TOPO expression vector:* The encoding sequences were produced by PCR using the chromosomal DNA of *E. coli* strain K-12/MC1061 as a template. The YefM encoding sequence was amplified with the primers set forth in SEQ ID NOs: 1-2. The YoeB encoding sequence was amplified with the primers set forth in SEQ ID NOs: 3-4. The YefM and YoeB pair encoding sequence was amplified using the primers of SEQ ID NOs: 1 and 4. The PCR products were inserted into the pBAD-TOPO vector to generate pBAD-yefM, pBAD-yoeB, and pBAD-yefMyoeB constructs using the pBAD-TOPO TA cloning kit (Invitrogen). The generated constructs were introduced to *E. coli* strain TOP10.

*Growth rate analysis:* *E. coli* TOP10 bacteria transformed with pBAD-yefM, pBAD-yoeB, and pBAD-yefMyoeB were cultured in LB broth supplemented with 100 µg/ml ampicillin (LB-Amp) and incubated at 37 °C overnight. Following incubation, cultures were diluted in fresh LB-Amp and their optical density was adjusted to approximately 0.01 ( $A_{600}$ ). Each culture was then divided into two equal volumes. One volume was supplemented with 0.2% L-arabinose to induce expression of the target gene and the second volume was supplemented with 0.2%

D-glucose to suppress expression. All cultures were incubated at 37 °C and 200 rpm for up to 9 hours. Cell density was estimated periodically by optical absorbance at 600 nm. The effect of target gene induction on bacterial growth during the logarithmic growth phase was determined as described above with the exception that  
5 cultures were divided and supplemented with 0.2% L-arabinose, or 0.2% D-glucose at the time they had reached optical density of approximately 0.45 ( $A_{600}$ ).

**Colony formation analysis:** *E. coli* TOP10 bacteria harboring pBAD-*yefM*, pBAD-*yoeB*, or pBAD-*yefMyoeB*, were cultured in LB-Amp and incubated at 37 °C overnight. Following incubation the cultures were diluted to an  $A_{600}$  of 0.01 in a  
10 fresh LB-Amp and incubated at 37 °C until an absorbance of 0.5 at  $A_{600}$  was reached. The cultures were then diluted in ten-fold dilutions steps and applied as 5 µl droplets on LB-Amp agar plates containing L-arabinose at a concentration gradient of 0.2%, 0.1%, 0.05%, 0.02%, 0.005% and 0.0005%. An LB-Amp agar plate containing  
15 0.2% glucose was used as a negative control. All plates were incubated at 37 °C for at least 20 hours.

#### **Results:**

Growth of bacteria overexpressing YoeB or YefM alone was substantially reduced as compared with the control (Figure 3B). On the other hand, growth of bacteria overexpressing both YefM and YoeB remained normal (Figure 3C). Similar  
20 results were observed when the expression of YoeB and YefM was induced during the logarithmic growth phase of the bacteria (Figures 3D-F). In addition, an overexpression of either YoeB or YefM alone inhibited bacterial colony formation, while, on the other hand, colony formation was unaffected when both YoeB and YefM polypeptides were overexpressed (Figure 3G).

25 These results clearly indicate that YoeB and YefM polypeptides behave as a toxin-antitoxin pair.

**EXAMPLE 4*****Biophysical characterization of YefM antitoxin******Materials and methods:***

***Cloning, expression and purification of YefM from E. coli:*** The DNA  
5 fragment containing *yefM* coding sequence flanked by primer-encoded *BsrGI* and  
*HindIII* sites, was produced by a polymerase chain reaction (PCR) using *E. coli* K-  
12 MC1061 strain chromosome as template and oligonucleotide primers set forth  
in SEQ ID NOs: 5 and 2. The PCR product was digested with *BsrGI* and *HindIII*  
enzymes (New England Biolabs), cloned into the *BsrGI* and *HindIII* restriction  
10 sites of a pET42a expression vector (Novagen) in fusion to glutathione s-  
transferase (GST) and transformed into *E. coli* BL21(DE3) pLysS (Novagen).  
Transformed bacteria were cultured in 2YT broth at 37 °C and 200 rpm to an  
optical density ( $A_{600}$ ) of approximately 0.4. Polypeptide expression was induced  
by the addition of IPTG (2 mM). One hour following induction cells were  
15 harvested and re-suspended in a solution comprising phosphate buffer saline (pH  
7.3), 140 mM NaCl, 2.7 mM KCl, 10 mM  $\text{Na}_2\text{HPO}_4$ , 1.8 mM  $\text{KH}_2\text{PO}_4$ , protease  
inhibitor cocktail as recommended (Sigma), and 0.5 mM PMSF. The suspended  
cells were lysed via three passages through a French-press cell (1400 psi) and the  
insoluble material was removed by centrifugation for 20 min at 20,000 x *g* at 4 °C,  
20 followed by filtration through a 0.45 µm membrane. The lysate supernatant was  
applied onto a 1 ml glutathione sepharose column (Amersham Pharmacia Biotech)  
pre-equilibrated with PBS (pH 7.3). The YefM-GST fusion protein was eluted  
using 10 ml of a solution comprising 50 mM Tris-HCl (pH 8.0) and 10 mM  
glutathione. YefM was separated from GST by incubation at 37 °C in the presence  
25 factor Xa protease (Novagen; 16 units of protease per 1 mg YefM fusion).  
Following 14 hours incubation, the protease reaction was terminated by the  
addition of 1mM PMSF.

Two different methods were applied for YefM purification. In one method,  
GST and linker polypeptide (~40 kDa) was separated from YefM (~11 kDa) using a  
30 Sepharose HR 10/30 (FPLC) gel filtration column (Amersham Pharmacia Biotech)  
and a FPLC instrument (Pharmacia LKB). Polypeptides were eluted with PBS (pH  
7.3), 0.8 ml/min, and a peak that included the ~11 kDa YefM polypeptides was

collected after 13 min. Fractions containing the YefM polypeptide were completely purified using 1  $\mu$ mol of immobilized glutathione agarose (Sigma) agitated for 16 hours at room temperature. At this point, the purity of YefM was greater than 95% (estimated by Coomassie staining of SDS-PAGE).

5 In another purification method, the YefM and GST mixture was divided into 0.5 ml aliquots, boiled for 10 minutes and then centrifuged at 14,000 rpm for 10 minutes. The supernatants, containing purified YefM, were collected and united.

The YefM concentration was estimated based on tyrosine absorbance in 0.1M KOH was used. Polypeptide concentrations were calculated using the  
10 extinction coefficients of 2391  $M^{-1} cm^{-1}$  (293.2 nm in 0.1 M KOH) for single tyrosine.

The molecular mass of YefM was verified by matrix-assisted laser desorption ionization time-of-flight (MALDI-TOF) mass spectrometry using a voyager-DE STR Biospectrometry workstation (Applied Biosystems) and using  $\alpha$ -Cyano-4-  
15 hydroxycinnamic acid as the matrix.

**Circular Dichroism (CD):** CD spectra were obtained by using an AVIV 202 spectropolarimeter equipped with temperature-controlled sample holder and a 5 mm path length cuvette. Mean residual ellipticity,  $[\theta]$ , was calculated as,

$$[\theta] = [100 \times \theta \times m] / [c \times L]$$

20 where  $\theta$  is the observed ellipticity,  $m$  is the mean residual weight,  $c$  is the concentration in mg/ml, and  $L$  is the path length in centimeters.

All experiments were performed in PBS (pH 7.3) at polypeptide concentration of 10  $\mu$ M. For thermal denaturation experiments, samples were equilibrated at each temperature for 0.5 min and CD ellipticity at 222 nm and 217  
25 nm was averaged for 1 min.

**Fourier Transform Infrared Spectroscopy (FTIR):** Spectra were recorded using a Nicolet Nexus 470 FT-IR spectrometer with a DTGS detector. A sample of 1  $\mu$ g of lyophilized YefM, suspended in 30  $\mu$ l PBS in D<sub>2</sub>O (pH 7.3), was dispensed on a CaF<sub>2</sub> plate. Spectrometer measurements were taken using a 4  $cm^{-1}$  resolution  
30 and 2,000 scans averaging and the transmittance minima values were determined by the OMNIC analysis program (Nicolet).

**Amino acid composition and charge-hydrophobicity values analysis:** The occurrence rate of each amino acid in the YefM family of polypeptides ( $P_{Mi}$ ) was determined by averaging its 30 frequencies in 30 YefM homologue sequences. The general amino acid occurrence rates ( $P_{Gi}$ ) were compiled by the Rockerfeller authors using the NCBI database (22). The relative differences between the occurrence rates of amino acids in YefM polypeptides and in general polypeptides was evaluated as  $(P_{Mi} - P_{Gi}) / P_{Gi}$ . The variances of these ratios were calculated as:  $\text{Var}(P_{Mi}) / (P_{Gi})^2$ . The overall hydrophobicity and net charge values of YefM family of polypeptides were calculated and plotted according to Uversky *et al.* (3).

**YefM stability analysis:** Overnight culture of *E. coli* carrying the pBAD-yefM plasmid was grown at 37 °C /200 rpm in LB broth to stationary phase ( $\text{OD}_{600} = 1.4$ ). YefM expression was then induced for 10 min with 0.2% L-arabinose and subsequently treated with 200 µg/ml rifampicin and 0.2% glucose to repress further expression from pBAD promoter. Aliquots of 2 ml were removed before and at 15 min intervals after repression, and the cellular YefM polypeptide was quantitatively analyzed by western blot. Densitometer assessment of YefM was effected using ImageScanner (Amersham Biosciences) and the ImageMaster 1D prime (ver. 3.01) program (Amersham Biosciences).

### Results:

A far UV circular dichroism (CD) spectra of the purified YefM polypeptide (in both purification methods) at increasing temperatures (25, 37 and 42 °C) is illustrated in Figure 4A. The spectra indicate a typical random-coil pattern, according to Jenness *et al.* (25), with a minimum in the vicinity of 200 nm with only slight changes in spectra due to temperature increase. An FTIR spectrum of the purified YefM at room temperature is illustrated in Figure 4B. The spectrum shows a transmittance minimum at  $1643 \text{ cm}^{-1}$  which is indicative of a random-coil structure according to Haris and Chapman (26). Thermal denaturation curve further indicates a consistent predominant random-coil structure of YefM which is maintained at 2 °C to 80 °C range (Figure 4C). The unfolded state of YefM is further supported by its extraordinary solubility during boiling (Figure 4D).

In order to get insight into the structural stability of the YefM in its native state within cells, a short expression of YefM was effected followed by its full



repression under stationary growth. Analysis of YefM levels in *E. coli*, before and after repression at different intervals, revealed that native YefM has an *in vivo* half-life of approximately one hour (Figure 7), which is characteristic to an antitoxin.

These results clearly indicate that YefM is an unfolded and unstable polypeptide *in vivo*.

### EXAMPLE 5

#### *Biophysical characterization of YoeB toxin*

##### *Materials and methods:*

10        **Cloning, expression and purification of YoeB from *E. coli*:** The DNA fragment containing *yefM-yoeB* coding sequence was produced by a polymerase chain reaction (PCR) using *E. coli* K-12 MC1061 strain chromosome as template and oligonucleotide primers set forth in SEQ ID NOs: 5 and 132. The PCR product was cloned into the pTrcHis2 expression vector (Invitrogen) in fusion to myc-epitope and his-tag, to generate pTMB. The plasmid was transformed into *E. coli* TOP10 strain (Invitrogen). Transformed bacteria were cultured in 2YT broth at 37 °C and 200 rpm to an optical density ( $A_{600}$ ) of approximately 0.4. Polypeptide expression was induced by the addition of IPTG (2 mM). Following one hour induction, cells were harvested and re-suspended in a Buffer A (phosphate buffer saline, pH 8.0; 50 mM  $\text{Na}_2\text{HPO}_4\text{-NaOH}$ ; 0.3 M NaCl; and 0.5 mM PMSF). The suspended cells were lysed via three passages through a French-press cell (1400 psi) and the insoluble material was removed by centrifugation for 20 min at 20,000 x g at 4 °C, followed by filtration through a 0.45  $\mu\text{m}$  membrane. The lysate supernatant was applied onto a Ni-CAM HC resin (Sigma) packed in a XG 16/20 FPLC column (Amersham Biosciences) pre-equilibrated with Buffer A. Following column wash, polypeptides were eluted with buffer A and 250 mM imidazole solution, in a single broad peak representing the purified YoeB-His (in a small number of fractions) or YoeB-His together with YefM (in most fractions). When eluted alone, YoeB-His purity was at least 90% as estimated by SDS-PAGE. 20  
30        Coomassie-blue staining.

Eluted YefM and YoeB-His complex was applied to HiPrep 16/10 Q XL column and pre-equilibrated with Buffer B (20 mM Tris-HCl, pH 8.0). Elution was

performed with developing NaCl gradient from 0.02 to 1 M in buffer B. The YefM : YoeB-His complex was eluted at approximately 650 mM NaCl. The complex was also separated using an analytic reverse-phase C<sub>18</sub> column (Vydac) with increasing gradient of 0 to 80% acetonitrile and 0.1% trifluoroacetic acid. YefM and YoeB-His polypeptides were eluted in a single peak in approximate 50% acetonitrile. In all above cases, elution was monitored at A<sub>280</sub>.

The identity of YefM and YoeB-His was verified using protein spots isolation from Coomassie blue stained gels and was accomplished by mass spectrometry, according to established protocols (Bandow, J.E., Becher, D., Buttner, K., Hochgrafe, F., Freiberg, C., Brotz, H. and Hecker, M. (2003) *Proteomics*, 3, 299-306). Briefly, protein spots were excised from stained gels and the gel pieces were treated trypsin solution (Pomega) for 16 h at 37 °C. Peptides were extracted from gel onto a sample plate for MALDI-MS. Obtained peptides masses were determined in the positive ion reflector mode in a Voyager-DE STR mass spectrometer (Applied Biosystems). Peptide mass fingerprints were compared to databases using the MS-Fit program (<http://prospector.ucsf.edu>). To determine the concentrations of YoeB-His and YefM polypeptides, tyrosine and tryptophan absorbance measurements in 0.1 M KOH were used. YefM concentration was calculated using the extinction coefficient of 2381 M<sup>-1</sup>cm<sup>-1</sup> at 293.2 nm for single tyrosine (4 tyr). YoeB-His concentration was calculated using extinction coefficient at 280 nm of 1507 M<sup>-1</sup>cm<sup>-1</sup> for single tyrosine (6 tyr) and 5377 M<sup>-1</sup>cm<sup>-1</sup> for single tryptophan (4 trp). Circular Dichroism (CD) spectra were obtained as described in Example 4 hereinabove. For thermal denaturation experiments, the sample temperature was equilibrated for 30 sec at each temperature interval and the ellipticity at 222 nm was averaged for 1 min. All experiments were performed in PBS, pH 7.3.

#### **Results:**

The YoeB-His and YefM polypeptides co-eluted using nickel column chromatography (Figure 9A), ion-exchange chromatography on a Q-sepharose column (Figure 9B) and RP-HPLC chromatography using a C<sub>18</sub> analytical column (Figure 9C), indicating a toxin-antitoxin complex.

The structure of purified YoeB-His toxin, as indicated from the far-UV

circular dichroism (CD) spectrum (Figure 10A), is consistent with a well-folded protein containing at least 50%  $\alpha$ -helical secondary structure. The secondary structure content of the toxin remains nearly unchanged between 4 - 37 °C. A near-UV CD analysis of YoeB-His also showed stability over this temperature range (Figure 10B) indicating that the tertiary structure of the toxin remains virtually unchanged as well. In addition, the YoeB-His exhibits full structural reversibility within the 4 - 37 °C temperature range (Figure 10A).

In order to determine the thermodynamic stability, YoeB-His underwent thermal denaturation between 2 and 80 °C monitored by CD ellipticity at 222 nm in neutral buffer. As can be seen in Figure 10C, a sharp increase in ellipticity slope was observed during the melting phase at approximately 60 °C. Cooling back from 80 °C to 2 °C could not bring to any observed renaturation, indicating that YoeB-His polypeptide could not regain its native conformation following such melt. In order to identify the melting point of the toxin, YoeB-His was partially melted and then cooled back repeatedly, each time raising the target temperature in about 5 °C increments. Conformational changes were monitored by measuring the CD ellipticity at 222 nm. The analysis shows structural reversibility of YoeB-His at a temperature ranging from 4 to 56 °C (Figures 11A-B). However, the YoeB-His polypeptide was unable to refold following melting at 60 °C (Figure 11C), indicating that the polypeptide melting point ( $T_M$ ) is approximately 60 °C.

## EXAMPLE 6

### *Identification of YefM recognition determinants*

#### *Materials and methods:*

*Cloning, expression, and purification of YefM from E. coli:* performed as described in Example 4 above.

*Cloning, expression, and purification of GST-YoeB from E. coli:* DNA fragment containing the coding sequence of *yoeB*, flanked by primer-encoded *EcoRI* and *HindIII* sites, was produced by a polymerase chain reaction using *E. coli* K-12 MC1061 strain chromosome as template and oligonucleotide primers set forth in SEQ ID NOs:1 and 132. The PCR product was digested with *EcoRI* and *HindIII* enzymes (New England Biolabs), cloned into the *EcoRI* and *HindIII* restriction sites

of the pET42a expression vector in fusion to GST, and transformed into *E. coli* BL21(DE3) pLysS. Bacteria were grown, expressed and lysed in the same manner described above for GST-YefM fusion protein. The supernatant was applied onto a 1 ml glutathione sepharose column (Amersham Pharmacia Biotech) pre-equilibrated with PBS (pH 7.3). The bound protein was eluted using 10 ml of 50 mM Tris-HCl (pH 8.0), 10 mM glutathione. Eluted fractions containing the GST-YoeB fusion protein were collected and quantitatively assessed by Coomassie staining of SDS-PAGE.

**Peptide array analysis:** Tridecamer peptides corresponding to consecutive overlapping sequences of the YefM polypeptide were arrayed on a cellulose membrane matrix and covalently bound to a Whatman 50 cellulose support (Whatman). Approximately 50 µg aliquots of soluble GST-YoeB fusion were examined for their selective peptide binding ability, on the basis of YefM-YoeB putative interaction.

For low stringency binding the cellulose membrane was briefly washed in 100% ethanol, washed three times with Tris-buffered saline (TBS; 50 mM Tris-HCl pH 7.5, 150 mM NaCl), then blocked for 4 hours using 5% (w/v) non-fat milk in TBS. The membrane was then washed three times in TBS + 0.1% (v/v) tween 20 (TBS-T) and incubated with 10 ml GST-YoeB solution at 4 °C and slow shaking for 14 hours.

For high stringency binding the washing steps were extensive and multiple and the blocking solution washing step was reduced to a single brief wash.

Following incubation, the membrane was washed once in TBS-T then supplemented with 10 ml suspension comprising TBS, mouse anti-GST antibody and horseradish peroxidase conjugated goat anti-mouse antibody in the appropriate titers. Following 1 hour incubation at room temperature the membrane was briefly washed with TBS-T and TBS. Bound GST-YoeB proteins were detected through an enhanced chemiluminescence reaction following an exposure to a sensitive film.

**Western blot analysis:** Bacterial culture aliquots (2 ml) were centrifuged at 14,000 rpm for 5 min at 4°C and re-suspended in 80 µl of double-distilled water. Sixty µl suspension aliquots were added to 20 µl aliquots of 4 x sample buffer, and the remaining 20 µl aliquots were used to quantify the total polypeptide using the

Coomassie plus protein assay reagent (Pierce). Aliquots containing equal total polypeptide amounts were loaded on a tris-tricine SDS 15% polyacrylamide slab gel. After electrophoresis, the proteins were electroblotted to PVDF membrane filters (Bio-Rad) and exposed to anti-YefM serum raised in rabbit. The membrane was then incubated with peroxidase-conjugated anti-rabbit antibodies and the presence of YefM was determined by an enhanced chemiluminescence reaction following by an exposure to a sensitive film.

*Surface plasmon resonance analysis:* Binding affinities were evaluated by surface plasmon resonance (SPR) using BIAcore™2000 (BIAcore Inc., NJ). Approximately 30 resonance units of the peptide having the amino acid sequence set forth in SEQ ID NO: 7, denoting to the YefM antitoxin binding determinant sequence, was immobilized onto a research grade sensor chip CM5 using amine coupling kit (BIAcore) as described by the manufacturer. Suspensions of 12.5, 25, and 50 nM GST-YoeB fusion polypeptide in 50 mM Tris (pH 7.2) were passed over the chip surface at room temperature and a flow rate of 10 µl / min. The chip surface was regenerated with 10 mM HCl after each run and re-equilibrated with Tris buffer. Sensogram data were analyzed using the BIAevaluation 3.0 software package. The rate constants were calculated for the binding data using local fitting for the data set as described in the BIAevaluation 3.0 manual with the 1:1 Langmuir binding model.

#### Results:

Three putative YefM fragments capable of binding GST-YoeB fusion protein were identified in a peptide array using a low stringency procedure (Figure 6A). A first region comprises three tridecamer peptides (YefM<sub>11-23</sub>–YefM<sub>15-27</sub>) in decreasing binding capacity, which includes the sequence RTISYSEARONLSATMM (the underlined sequence represents a putative binding site; set forth in SEQ ID NO: 129). A second region includes a single YefM<sub>33-45</sub> peptide sequence, APILITRQNGEAC (set forth in SEQ ID NO: 130). A third region includes the peptides YefM<sub>75-87</sub> and YefM<sub>77-89</sub> which cover the MDSIDSLKSGKGTEKD (set forth in SEQ ID NO: 131). In a high stringency procedure the examined sites were extended to include YefM<sub>8-31</sub> as the first region, YefM<sub>29-48</sub> as the second region and YefM<sub>72-92</sub> as the third region. The shift between each arrayed tridecamer peptide was reduced to a single amino acid which resulted in identifying the YefM<sub>11-23</sub>

peptide, having the amino acid sequence set forth in SEQ ID NO: 7, as a sequence containing the antitoxin binding determinant (Figure 6B).

In replacing the amino acid leucine in position 22 of the YefM<sub>11-23</sub> peptide to alanine or to glycine only attenuated the binding capacity of GST-YoeB. On the other hand, replacing the amino acid arginine in position 19 of the YefM<sub>11-23</sub> peptide, with either alanine or glycine (set forth SEQ ID NOs: 8 and 9, respectively) totally negated the binding capacity of the YefM<sub>11-23</sub> peptide analog with GST-YoeB (Figure 6C).

Surface plasmon resonance (BIAcore) analysis was used to quantitative determine the affinity between the YoeB toxin and the YefM<sub>11-23</sub> peptide fragment. The recognition determinant sequence peptides were immobilized onto the sensor chip and the kinetics of GST-YoeB binding and dissociation was estimated at 12.5, 25, and 50 nM concentrations (Figure 8). According to data analysis, a  $k_a$  of  $3.06 \times 10^3$  ( $M^{-1}s^{-1}$ ) and a  $k_d$  of  $1.22 \times 10^3$  ( $M^{-1}s^{-1}$ ) were calculated (arithmetic mean). Accordingly, an equilibrium constant ( $K_D$ ) of 0.4  $\mu M$  was determined for the YoeB-YefM<sub>11-23</sub> complex. This dissociation constant is consistent with a specific binding between the toxin and the peptide fragment.

The isolated binding determinant of the YefM antitoxin can be utilized to identify agents capable of preventing or disrupting the YoeB-YefM toxin-antitoxin binding and thereby to induce death of bacteria expressing the YoeB and YefM toxin-antitoxin pair.

It is appreciated that certain features of the invention, which are, for clarity, described in the context of separate embodiments, may also be provided in combination in a single embodiment. Conversely, various features of the invention, which are, for brevity, described in the context of a single embodiment, may also be provided separately or in any suitable subcombination.

Although the invention has been described in conjunction with specific embodiments thereof, it is evident that many alternatives, modifications and variations will be apparent to those skilled in the art. Accordingly, it is intended to embrace all such alternatives, modifications and variations that fall within the spirit

and broad scope of the appended claims. All publications, patents, patent applications and sequences identified by their accession numbers mentioned in this specification are herein incorporated in their entirety by reference into the specification, to the same extent as if each individual publication, patent, patent application or sequence identified by their accession number was specifically and individually indicated to be incorporated herein by reference. In addition, citation or identification of any reference in this application shall not be construed as an admission that such reference is available as prior art to the present invention.

## REFERENCES CITED

(Additional references are cited hereinabove)

1. Anfinsen, C.B. (1973) *Science* **181**, 223-230.
2. Schweers, O., Schönbrunn-Hanebeck, E., Marx, A. and Mandelkow, E. (1994) *J. Biol. Chem.* **269**, 24290-24297.
3. Uversky, V.N., Gillespie, J.R. and Fink, A.L. (2000) *Proteins Struct. Funct. Genet.* **41**, 415-427.
4. Uversky, V.N. (2002) *Prot. Sci.* **11**, 739-756.
5. Uversky, V.N. (2002) *Eur. J. Biochem.* **269**, 2-12.
6. Dunker, A.K., Lawson, J.D., Brown, C.J., Williams, R.M., Romero, P., Oh, J.S., Oldfield, C.J., Campen, A.M., Ratliff, C.M., Hipps, K.W., Ausio, J., Nissen, M.S., Reeves, R., Kang, C.-H., Kissinger, C.R., Bailey, R.W., Griswold, M.D., Chiu, W., Garner, E.C. and Obradović, Z. (2001) *J. Mol. Graph. Model.* **19**, 26-59.
7. Dobson, C.M. (1999) *Trends Biochem. Sci.* **24**, 329-332.
8. Rochet, J.C. and Lansbury, P.T.Jr. (2000) *Curr. Opin. Struct. Biol.* **10**, 60-68.
9. Gazit, E. (2002) *Curr. Med. Chem.* **9**, 1725-1735.
10. Dunker, A.K., Brown, C.J., Lawson, J.D., Iakoucheva, L.M. and Obradović, Z. (2002) *Biochemistry* **41**, 6573-6582.
11. Gazit, E. and Sauer, R.T. (1999) *J. Biol. Chem.* **274**, 2652-2657.
12. Lehnher, H., Maguin, E., Jafri, S. and Yarmolinsky, M.B. (1993) *J. Mol. Biol.* **233**, 414-428.
13. Lehnher, H. and Yarmolinsky, M.B. (1995) *Proc. Natl. Acad. Sci. USA* **92**, 3274-3277.
14. Christensen, S.K. and Gerdes, K. (2003) *Mol. Microbiol.* **48**, 1389-1400.
15. Pedersen, K., Zavialov, A.V., Pavlov, M.Y., Elf, J., Gerdes, K. and Ehrenberg, M. (2003) *Cell* **112**, 131-140.
16. Pedersen, K., Christensen, S.K. and Gerdes, K. (2002) *Mol. Microbiol.* **45**, 501-510.
17. Christensen, S.K., Mikkelsen, M., Pedersen, K. and Gerdes, K. (2001) *Proc. Natl. Acad. Sci. USA* **98**, 14328-14333.



18. Gerdes, K. (2000) *J. Bacteriol.* **182**, 561-572.
19. Aizenman, E., Engelberg-Kulka, H. and Glaser, G. (1996) *Proc. Natl. Acad. Sci. USA* **93**, 6059-6063.
20. Altschul, S.F., Madden, T.L., Schäffer, A.A., Zhang, J., Zhang, Z., Miller, W. and Lipman, D.J. (1997) *Nucleic Acids Res.* **25**, 3389-3402.
21. Thompson, J.D., Higgins, D.G. and Gibson, T.J. (1994) *Nucleic Acids Res* **22**, 4673-4680.
22. <http://prowl.rockefeller.edu/aainfo/masses.htm>.
23. Pomerantsev, A.P., Golovliov, I.R., Ohara, Y., Mokrievich, A.N., Obuchi, M., Norqvist, A., Kuoppa, K. and Pavlov, V.M. (2001) *Plasmid* **46**, 210-222.
24. Grady, R. and Hayes, F. (2003) *Mol. Microbiol.* **47**, 1419-1432.
25. Jeness, D.D., Sprecher, C.A. and Johnson, W.C. (1976) *Biopolymers* **15**, 513-521.
26. Gazit, E. and Sauer, R.T. (1999) *J. Biol. Chem.* **274**, 16813-16818.
27. Oberer, M., Lindner, H., Glatter, O., Kratky, C. and Keller, W. (1999) *Biol. Chem.* **380**, 1413-1420.
28. Thi, M.H.D., Messens, J., Wyns, L. and Backmann, J. (2000) *J. Mol. Biol.* **299**, 1373-1386.
29. Camacho, A.G., Misselwitz, R., Behlka, J., Ayora, S., Welfle, K., Meinhardt, A., Lara, B., Saenger, W., Welfle, H. and Alonso, J.C. (2002) *Biol. Chem.* **383**, 1701-1713.
30. Romero, P., Obradović, Z., Li, X., Garner, E.C., Brown, C.J. and Dunker, K. (2001) *Proteins Struct. Funct. Genet.* **42**, 38-48.
31. Vihinen, M., Torkkila, E. and Riikonen, P. (1994) *Proteins* **19**, 141-149.
32. Radivojac, P., Obradović, Z., Brown, C.J. and Dunker, A.K. (2003) *Pac. Symp. Biocomput.* **8**, 216-227.

## WHAT IS CLAIMED IS:

1. A method of identifying a molecule capable of inducing death of a bacterial cell, the method comprising:

- (a) exposing toxin and antitoxin polypeptides of a toxin-antitoxin pair produced by the bacterial cell to a plurality of molecules; and
- (b) identifying a molecule of said plurality of molecules capable of preventing or disrupting binding between said antitoxin and said toxin polypeptides, thereby identifying the molecule capable of inducing death of the bacterial cell.

2. The method of claim 1, wherein step (a) is effected by administering said plurality of molecules to bacteria expressing said toxin and antitoxin polypeptides.

3. The method of claim 1, wherein said antitoxin polypeptide is an unfolded polypeptide.

4. The method of claim 1, wherein said antitoxin polypeptide includes an amino acid sequence selected from the group consisting of SEQ ID NOs. 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122 and 124.

5. The method of claim 1, wherein said antitoxin polypeptide is encoded by a polynucleotide sequence selected from the group consisting of SEQ ID NOs. 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64 and 66.

6. The method of claim 1, wherein said toxin polypeptide includes an amino acid sequence selected from the group consisting of SEQ ID NOs. 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 93, 95, 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, 123 and 125.

7. The method of claim 1, wherein said toxin polypeptide is encoded by a polynucleotide sequence selected from the group consisting of SEQ ID NOs. 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65 and 67.

8. A method of treating an infection of bacteria in a subject, comprising preventing or disrupting binding between a toxin and an antitoxin polypeptides of a toxin-antitoxin pair produced in the bacteria, thereby treating the infection of the bacteria in the subject.

9. The method of claim 8, wherein said preventing or disrupting binding between said toxin and said antitoxin polypeptides is effected by providing to the subject an agent selected from the group consisting of:

- (a) a compound which specifically binds to said antitoxin or said toxin;
- (c) an antisense polynucleotide capable of specifically hybridizing with an mRNA transcript encoding said antitoxin;
- (d) a ribozyme which specifically cleaves transcripts encoding said antitoxin; and
- (e) a small interfering RNA (siRNA) molecule which specifically cleaves said antitoxin transcripts.

10. The method of claim 9, wherein said compound is selected from the group consisting of a peptide, a polynucleotide, a polysaccharide, a small organic compound and a non-biological compound.

11. The method of claim 9, wherein said compound is an antibody or an antibody fragment.

12. The method of claim 8, wherein said bacteria are pathogenic bacteria.

13. The method of claim 1, wherein said antitoxin polypeptide is an unfolded polypeptide.

14. The method of claim 8, wherein said antitoxin polypeptide includes an amino acid sequence selected from the group consisting of SEQ ID NOs. 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122 and 124.

15. The method of claim 8, wherein said antitoxin polypeptide is encoded by a polynucleotide sequence selected from the group consisting of SEQ ID NOs. 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64 and 66.

16. The method of claim 8, wherein said toxin polypeptide includes an amino acid sequence selected from the group consisting of SEQ ID NOs. 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65 and 67.

17. The method of claim 8, wherein said toxin polypeptide is encoded by a polynucleotide selected from the group consisting of SEQ ID NOs. 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65 and 67.

18. The method of claim 8, wherein the subject is a mammal.

19. The method of claim 8, wherein the subject is a human.

20. A pharmaceutical composition for treating an infection of bacteria, comprising an effective amount of an agent capable of preventing or disturbing binding between a toxin and an antitoxin polypeptides of a toxin-antitoxin pair produced in the bacteria.

21. The pharmaceutical composition of claim 20, wherein said agent is a compound which specifically binds to said antitoxin or said toxin.

22. The pharmaceutical composition of claim 21, wherein said compound is selected from the group consisting of a peptide, a polynucleotide, a polysaccharide, a small organic compound and a non-biological compound.

23. The pharmaceutical composition of claim 22, wherein said peptide is derived from said toxin or said antitoxin.

24. The pharmaceutical composition of claim 22, wherein said peptide includes an amino acid sequence selected from group consisting of SEQ ID NOs: 7-9.

25. The pharmaceutical composition of claim 21, wherein said compound is an antibody or an antibody fragment.

26. The pharmaceutical composition of claim 20, wherein said agent is a polynucleotide capable of specifically hybridizing with an mRNA transcript encoding said antitoxin.

27. The pharmaceutical composition of claim 20, wherein said agent is a ribozyme which specifically cleaves transcripts encoding said antitoxin.

28. The pharmaceutical composition of claim 20, wherein said agent is a small interfering RNA (siRNA) molecule which specifically cleaves said antitoxin transcripts

29. A method of identifying toxin and antitoxin polypeptides of a toxin-antitoxin pair, comprising:

- (a) identifying bacterial polynucleotide sequences at least partially homologous to polynucleotide sequences encoding known bacterial toxin and antitoxin polypeptides to thereby obtain a plurality of toxin and antitoxin encoding sequences; and
- (b) determining a chromosomal position of each of said plurality of sequences, wherein toxin and antitoxin encoding sequences which are

chromosomally positioned at a distance from each other which is no greater than a predetermined value encode a toxin-antitoxin pair.

30. The method of claim 29, wherein said predetermined value is ranging between 10 base pair to 150 base pair.

31. A peptide comprising at least 10 and no more than 50 amino acids, the peptide comprises the sequence set forth in SEQ ID NO: 7.

32. A peptide comprising at least 10 and no more than 50 amino acids, the peptide comprises the sequence set forth in SEQ ID NO: 8.

33. A peptide comprising at least 10 and no more than 50 amino acids, the peptide comprises the sequence set forth in SEQ ID NO: 9.

1/16




Fig. 1

2/16

<i>E. coli</i>	.....
<i>Y. enterocolitica A</i>	.....
<i>P. fluorescens</i>	.....
<i>F. tularensis</i>	.....
<i>A. actinomycetemcomitans</i>	.....
<i>N. europaea A</i>	.....
<i>Synechocystis</i> sp. PCC 7942	.....
<i>N. europaea B</i>	.....
<i>P. putida</i>	.....
<i>P. syringae</i>	.....
<i>B. cepacia</i>	.....
<i>C. burnetii</i>	.....
<i>S. pneumoniae</i>	.....
<i>E. faecium</i>	.....
<i>S. aureus</i>	.....
<i>A. tumefaciens</i>	.....
<i>Hostoc</i> sp. PCC 7120	.....
<i>Synechocystis</i> sp. PCC 6803 A	.....
<i>M. tuberculosis</i>	.....
<i>M. bovis</i>	.....
<i>S. coelicolor</i>	.....
<i>S. viridochromogenes</i>	.....
<i>T. ferrooxidans</i>	.....
<i>N. europaea C</i>	.....
<i>R. conorii</i>	.....
<i>Synechocystis</i> sp. PCC 6803 B	.....
<i>S. typhimurium</i>	.....
<i>K. pneumoniae</i>	.....
<i>Y. enterocolitica B</i>	.....
Phage P1 - Phd	.....

Fig. 2a





4/16




Fig. 3a




Fig. 3b




Fig. 3c




Fig. 3d




Fig. 3e




Fig. 3f

5/16




Fig. 3g




Fig. 4a

6/16




Fig. 4b




Fig. 4c




Fig. 4d

7/16




Fig. 5a




Fig. 5b

8/16




Fig. 6a




Fig. 6b




Fig. 6c




Fig. 7a





Fig. 7b





11/16




Fig. 9a

12/16




Fig. 9b

13/16




Fig. 9c

14/16




Fig. 10a




Fig. 10b

15/16




Fig. 10c




Fig. 11a

16/16




Fig. 11b




Fig. 11c

1  
SEQUENCE LISTING

<110> Gazit , Rhud  
Cherny, Izhack

<120> NOVEL ANTIBACTERIAL AGENTS AND METHODS OF IDENTIFYING AND  
UTILIZING SAME

<130> 26920

<160> 131

<170> PatentIn version 3.2

<210> 1  
<211> 19  
<212> DNA  
<213> Artificial sequence

<220>  
<223> Single strand DNA oligonucleotide

<400> 1  
atgaactgta caaaagagg 19

<210> 2  
<211> 23  
<212> DNA  
<213> Artificial sequence

<220>  
<223> Single strand DNA oligonucleotide

<400> 2  
gacaagctta gtttcaactca atg 23

<210> 3  
<211> 19  
<212> DNA  
<213> Artificial sequence

<220>  
<223> Single strand DNA oligonucleotide

<400> 3  
gtgaaactaa tctggtctg 19

<210> 4  
<211> 26  
<212> DNA  
<213> Artificial sequence

<220>  
<223> Single strand DNA oligonucleotide

<400> 4  
tgaagctttt caataatgat aacgac 26

<210> 5  
<211> 24  
<212> DNA  
<213> Artificial sequence

<220>  
<223> Single strand DNA oligonucleotide

<400> 5  
gtacaatgaa ctgtacaaaa gaag 24

<210> 6  
<211> 26  
<212> DNA  
<213> Artificial sequence

<220>

2

&lt;223&gt; Single strand DNA oligonucleotide

&lt;400&gt; 6

cctttgaagc ttttcaataa tgataa

26

&lt;210&gt; 7

&lt;211&gt; 13

&lt;212&gt; PRT

&lt;213&gt; Artificial sequence

&lt;220&gt;

&lt;223&gt; Synthetic peptide

&lt;400&gt; 7

Arg	Thr	Ile	Ser	Tyr	Ser	Glu	Ala	Arg	Gln	Asn	Leu	Ser
1			5						10			

&lt;210&gt; 8

&lt;211&gt; 13

&lt;212&gt; PRT

&lt;213&gt; Artificial sequence

&lt;220&gt;

&lt;223&gt; Synthetic peptide

&lt;400&gt; 8

Arg	Thr	Ile	Ser	Tyr	Ser	Glu	Ala	Ala	Gln	Asn	Leu	Ser
1			5						10			

&lt;210&gt; 9

&lt;211&gt; 13

&lt;212&gt; PRT

&lt;213&gt; Artificial sequence

&lt;220&gt;

&lt;223&gt; Synthetic peptide

&lt;400&gt; 9

Arg	Thr	Ile	Ser	Tyr	Ser	Glu	Ala	Gly	Gln	Asn	Leu	Ser
1			5						10			

&lt;210&gt; 10

&lt;211&gt; 252

&lt;212&gt; DNA

&lt;213&gt; Actinobacillus actinomycetemcomitans

&lt;400&gt; 10

atgaatgtaa taagttattc tgcgtttcgt gcagaattgg caaccacact tgatcaggtg	60
gtacgagatc atagcccagt catgattacc agacaaaatg gcaaacacgc tgttgtaatg	120
agtttagaag atttcgcagc ttacgaagaa acggcttatt tattacgcag ccccaaaaat	180
agagagcgtt tattagcctc tattgaccag ctcaattcag gtaaaatcat cgaacgggaa	240
ctccaggaat ga	252

&lt;210&gt; 11

&lt;211&gt; 255

&lt;212&gt; DNA

&lt;213&gt; Actinobacillus actinomycetemcomitans

&lt;400&gt; 11

atgatttttag cttggacgga aaocgcctgg gaagattatc tttattggca gcaagttgat	60
aaaaagacgt tgttgogcat taataaaactt atccaaaata ttaccagatc acctttcgaa	120
ggottaggca atcctaaaacc tttaaaacat cagttatccg ggttttggtc tagaagaata	180
gataaagagc atcgtcttgt ataccaagta tcggatagcc atttaacgat tattcaatgc	240
cgctatcact actaa	255



<210> 12  
 <211> 255  
 <212> DNA  
 <213> *Agrobacterium tumefaciens*

<400> 12  
 atggcgaatg tgcgatttac cgagttcagg cagaactteg cgacccattt cgaccggggtt 60  
 ctggaaaccc gcgcgccatt gctcgtcacg cggcaaggca aagaggcggg cgtgggtgctt 120  
 gccgaaggag aatatgagag catgcaggaa acgctgcate tcctgtccaa cccggcaaat 180  
 gcctcaaggc ttgcgcgctc catggggcga cttgagcgcg gtgacaccat cgagcgggat 240  
 ccgaccgaag aatga 255

<210> 13  
 <211> 270  
 <212> DNA  
 <213> *Agrobacterium tumefaciens*

<400> 13  
 atgaagctcg tctggacgct gagttcatgg gacgactatg agttctggca aagaaccgat 60  
 gctcgcattg tcgagaaaat aaacgatctt atccgaaatg ccaaaccgac gccctttgca 120  
 gggcttggga aaccggagcc tctgaagggc gatatggcag gatattggtc tcggcggatt 180  
 accgccgagc atcggtttgt ctaccgtgta tccgggtocg gaagcgagca acggctggaa 240  
 gtcattcagt gccgcttcca ttaccaataa 270

<210> 14  
 <211> 246  
 <212> DNA  
 <213> *Burkholderia cepacia*

<400> 14  
 atgaacgtcc ttacttatag cgaggcgctg gccggcttca agcaggcgat ggacgaogtc 60  
 tgccgcgac acatacccat gctgatcagc aggcagacgg gcgaaaacgt ggtgatgggtt 120  
 tcgctcggcg atttcaatgc gatgcaggag accttgatc tggttgagtc gtegaagaac 180  
 gcccgccggc tcgcccgatc tatcgctcaa ctgaacgccg gcgggtcgac tgcgcgtgaa 240  
 ctgctg 246

<210> 15  
 <211> 252  
 <212> DNA  
 <213> *Burkholderia cepacia*

<400> 15  
 atgttcaccg acgacgcgtg ggaogattac ctgtattggc aagagaccga ccggaaggtc 60  
 gtgcgcaaga tcaacacgct gctggaggag tgccggcgcg atccttatcg cggtagggg 120  
 aaaccggagg cgttgatggg cagcatgagc ggattgtggt ctcggcgat cagcgtggcc 180  
 gaccgtcttg tctacttgcc gcgagacgga aagatctaag tgatcgctt tcgcttccac 240  
 tacgactgct ga 252

<210> 16  
 <211> 255  
 <212> DNA  
 <213> *Coxiella burnetii*

<400> 16  
 atgaacgtag ttacttttag cgaactcagg gcgcaactta aaaaaatctt ggatctttcc 60  
 gccgatcaac acgaacctgt cgtcgtaaa cggccaaata aagaaacat ggtcatttta 120

4

tctttaogcg actttgagggc tctaaaagaa acagcttatac tcttaagtaa cgaagctaata 180  
 ggggcccgtc ttcgtcagtc tatccgcagc ttaaaacaag gcaaggcaca aaaaaagaaa 240  
 ttaatggaag attaa 255

<210> 17  
 <211> 276  
 <212> DNA  
 <213> *Coxiella burnetii*

<400> 17  
 atgcaaattt ccttcacgcc cgaagcctgg gaagattatt tatattggca aaaattcgac 60  
 aaaaaaatgc ttcgacgcac taatgaacto attaaggatg ctatgcacga gcctttttcc 120  
 ggaaagggaa agccagaacc tttaaaattt gaattacaag gatattgggc aagacgatta 180  
 gatcaagaac atcgattggg ctacaaagtt ttagacgatt cgttaatgat tatcgccgca 240  
 agatttcact ataatcgctt taattctaaa aactga 276

<210> 18  
 <211> 279  
 <212> DNA  
 <213> *Escherichia coli*

<400> 18  
 atgaactgta caaaagagga gattgacatg cgtacaatta gctacagcga agcgcgtcag 60  
 aatttgcctg caacaatgat gaaagccgtt gaagatcatg ccccgatcct tattactcgt 120  
 cagaatggag aggccttggt tctgatgtca ctgaagaat acaactcgct ggaagagacg 180  
 gcttatctac tgcgctcccc cgctaaogcc cggagattga tggactcaat cgatagcctg 240  
 aaatcaggca aaggaacgga aaaggacatc attgagtga 279

<210> 19  
 <211> 255  
 <212> DNA  
 <213> *Escherichia coli*

<400> 19  
 gtgaaactaa tctggctctga ggaatcatgg gacgattatac tgtactggca ggaacagat 60  
 aagcgaattg ttaaaaagat caatgaactt atcaaagata cccgcagaac gccatttgaa 120  
 ggtaagggga agccagaacc cctgaaacat aatttgcag gcttctgggc ccgacgcatt 180  
 acagaggagc accgtctggg atacgcgggt accgacgatt caotgotcat tgcagcgtgt 240  
 cgttatcatt attga 255

<210> 20  
 <211> 270  
 <212> DNA  
 <213> *Enterococcus faecium*

<400> 20  
 atggaagcag tagcttattc aaatttccgc caaaatttac gtagttatat gaaacaagtt 60  
 aatgaggatg ctgaaacact tattgtaaca agtaaagatg tagaagatac agttgttgta 120  
 ttatcaaaaa gagattatga ttctatgcaa gaaacgttga gaacacttcc taataattac 180  
 gtcattgaaa aaattcgtcg aggagatgaa caattctcca aaggtgcatt taaaacacat 240  
 gacttaatcg aggttgaatc tgatgattaa 270

<210> 21  
 <211> 258  
 <212> DNA  
 <213> *Enterococcus faecium*

## 5

<400> 21  
 atgattaagg cttggtotga tgatgottgg gatgattatc tttattggca tgagcaagga 60  
 aacaaaagca atataaaaaa gattaacaag ttaataaaaag atatcgatcg ttcccccttt 120  
 gctggattag gaaaacctga gccattaaag catgatttat ctggaaaatg gtccagaaga 180  
 attacagatg aacatagact gatatataga gttgaaaatg aaacgatatt tattttattct 240  
 gcaaaagatc actattaa 258

<210> 22  
 <211> 258  
 <212> DNA  
 <213> Francisella tularensis

<400> 22  
 atgcaaaccg ttaattatc aactttttaga aatgaactat ctgattcaat ggatagagta 60  
 acaaaaaatc atagtcctat gattgtaact agaggttcaa aaaaagaagc agttgttatg 120  
 atgtcgttag aggattttta agcttatgaa gaaacagcct atcttatgag aagcatgaac 180  
 aactataaga gactacaaaa ttctattgat gaagtagaat ctggtttagc tatccaaaaa 240  
 gagttgattg aagaatga 258

<210> 23  
 <211> 207  
 <212> DNA  
 <213> Francisella tularensis

<400> 23  
 atgatacttt cttggccaac taatgottgg gaagattatc tatattggca aagcatagat 60  
 aagaaaaagc taaaacggat taatttgcta atcaaagaca ttatgagaaa tcaacttgag 120  
 ggattagag agcctgaacc tttgaagcat aatttctctg gttattggtc tagacgaata 180  
 gacaaagaac atctgaataa tctataa 207

<210> 24  
 <211> 222  
 <212> DNA  
 <213> Klebsiella pneumoniae

<400> 24  
 atgagaacgg ttaactatag cgaagcccgg caaatctgg ccgatgtgct ggaaagcgca 60  
 gtgacaggtg tacctgtgac cattaccgt cgtgggcata aatctgcagt catcattagt 120  
 gcagaagagt ttgaacgcta ccaggcgcc agaatggatg atgagttcgc ggotatcatg 180  
 gcggttcatg gtgatgagat caggagcct gcggataaat ga 222

<210> 25  
 <211> 369  
 <212> DNA  
 <213> Klebsiella pneumoniae

<400> 25  
 atgacgctgc agattatctc agcgggaagag ataatacagt ttcacgacag gctgctccgc 60  
 gtcacgctg gcgttgccgg tatgcccgat ccggggcgtg ccgaagcgat aatgtatagg 120  
 gtgctaaca aaattgaata tgaagggtg acagacgtgt ggcgactcgc tgcgatgoat 180  
 ctgctggcga tttctcgcgg tcatatattt aatgatggtg ataagcgtao ggcactgttt 240  
 atcacctgc tttttttaaa gcgaaatgga attatattgc cagcgaatcc agacttcgtc 300  
 ggcacgaccg tcgaggcagc agcagggcaa ettaccctgg aacagattgt cgcgcgtttg 360  
 cgtggatga 369

<210> 26  
 <211> 276  
 <212> DNA  
 <213> *Mycobacterium bovis*

<400> 26  
 atgagcatca gtgcgagcga ggcgaggcag cgctgtttc cactcatcga acaggtaaat 60  
 accgatcacc agccggtgcy gatcacctcc cgggcccggc atgcggtgct gatgtccgcc 120  
 gacgactacg acgcgtggca ggaaacggtc tatctgctgc gctcacccga gaacgccagg 180  
 cggttgatgg aagcggttgc ccgggataag gctgggcact cggctttcac caagtctgta 240  
 gatgagctgc gggagatggc cggcggcgag gactga 276

<210> 27  
 <211> 258  
 <212> DNA  
 <213> *Mycobacterium bovis*

<400> 27  
 gtgagaagcy tcaacttcga tcccgatgcc tgggaggact tcttgttctg gctggccgct 60  
 gatcgcaaaa cggcccgtcg gatcacccgg ttgatcggag aaattcagcg tgatccgttc 120  
 agcgggatcg gcaaaccga gccgctcaa ggtgagttgt cgggatactg gtcgcgccgg 180  
 atcgacgacg aacaccggct agtgtatcga gcgggcgacg acgaagtcac gatgctgaag 240  
 gcccgatacc actactga 258

<210> 28  
 <211> 276  
 <212> DNA  
 <213> *Mycobacterium tuberculosis*

<400> 28  
 atgagcatca gtgcgagcga ggcgaggcag cgctgtttc cactcatcga acaggtaaat 60  
 accgatcacc agccggtgcy gatcacctcc cgggcccggc atgcggtgct gatgtccgcc 120  
 gacgactacg acgcgtggca ggaaacggtc tatctgctgc gctcacccga gaacgccagg 180  
 cggttgatgg aagcggttgc ccgggataag gctgggcact cggctttcac caagtctgta 240  
 gatgagctgc gggagatggc cggcggcgag gactga 276

<210> 29  
 <211> 258  
 <212> DNA  
 <213> *Mycobacterium tuberculosis*

<400> 29  
 gtgagaagcy tcaacttcga tcccgatgcc tgggaggact tcttgttctg gctggccgct 60  
 gatcgcaaaa cggcccgtcg gatcacccgg ttgatcggag aaattcagcg tgatccgttc 120  
 agcgggatcg gcaaaccga gccgctcaa ggtgagttgt cgggatactg gtcgcgccgg 180  
 atcgacgacg aacaccggct ggtgtatcga gcgggcgacg acgaagtcac gatgctgaag 240  
 gcccgatacc actactga 258

<210> 30  
 <211> 297  
 <212> DNA  
 <213> *Neisseria europaea A*

<400> 30  
 ttggcagaat gtaatgtaca aataaatgta caattggaga accttatgga cgtatcact 60  
 tacagcactg ccagagccaa acttgccgac accatgaacc gcgtttgcca taaccatgaa 120  
 cctatcataa tcacacgcaa cggagaacaa tccgttgtaa tgatgtcgct cgacgacttc 180

7

aaggcgctgg aggaaacctc ttacctgctc cgtagcccaa agaatgcgaa gcggctgctg 240  
gaaagcatcg cagctcttga atcaggcaga ggcgaaacga gaagcctggc agagtga 297

<210> 31  
<211> 255  
<212> DNA  
<213> *Neisseria europea A*

<400> 31  
gtgaagctgg ttttctctga gcaggcctgg gaagactatt tgtactggca aaagacagac 60  
cgaaaaacgg tacagcgaat cgatacgctg gtgaaagaga ttacaagaac accacacgag 120  
ggtagcggca aacccgagcc actgaaacat gcgctgtcag gttattggte acgccgtatc 180  
aataacgagc accggatcgt ctataaaatt gcggatgact cgttgtttat tgctcaactg 240  
agataccact actga 255

<210> 32  
<211> 309  
<212> DNA  
<213> *Neisseria europea B*

<400> 32  
gtgtatcttt tttatacttg tacaatttat tgtgcaaatg aggttgccat gaaggttggt 60  
acttattcgc atgcgcgtaa tgcgttaaag tctatttttg atgatgtcat tcaggatgct 120  
gatgtaattg ttattagtcg tcgcgatgca gaaggtgatg ctgtggtgat gtcgctggat 180  
agctataaca gcatcatgga aacattgcac ttaaccagta atccagcaaa tgcgcgagcc 240  
ttagccaagg caattgctca ggataaggca ggacaagcac aagaccacc attgctttct 300  
gccgattaa 309

<210> 33  
<211> 261  
<212> DNA  
<213> *Neisseria europea B*

<400> 33  
gtgcgtgcc ttcgttttgt tcctgatgcy tgggaggctt acctttactg gcaagaccag 60  
gataaaaaaa cgctcaggcg attgaattct ctgattactg ccgcttctcg tgatccattt 120  
gttggtattg gcaaaccaga accactgcgg ggtgaattgt cgggttattg gtcaagacgt 180  
atcgatgaaa ctaatcgttt ggtttatcgt gttactgatg ttgagttagt gattattgct 240  
tgccgatttc actatgaata a 261

<210> 34  
<211> 243  
<212> DNA  
<213> *Neisseria europea C*

<400> 34  
atggcaatac taaacgcaac agaagcaaga gcgaggttgt acgccttaat tgatgaggcc 60  
gcagaaacac accagcctat tgtgattaag ggaaaaaggt caagtgcggt gcttttatcg 120  
gaggaagact ggaacgctat caacgagacg ctttacttgg tttctatccc gggaatgcgc 180  
gaatccatta tggaggggat gaaaactgat gtggatgagt gcagtaggga attggattgg 240  
taa 243

<210> 35  
<211> 261  
<212> DNA  
<213> *Neisseria europea C*

<400> 35  
 atgtgggagc tgcgatatac ccatcaagcg caaaaggatg caaaaaagct ggcatcgtct 60  
 gggccttaaag ataaggcaga ggagtgtgta gcggtgtgta ggaataatcc gtaccaaacc 120  
 ccacccccct atgaaaagct ggttggtgat ttggctggag cctgttcacg ccgtatcaac 180  
 atccagcaca ggctcgtgta tcaggtgttg gagcgggaga ggatagtaaa ggttttgcgt 240  
 atgtggactc attatgtgta g 261

<210> 36  
 <211> 408  
 <212> DNA  
 <213> Nostoc sp. PCC 7120

<400> 36  
 atgtactgga ttaaatttga aagtacacaa agggagcttt taatacttat gctttctaac 60  
 acttacactt acacacaagc acgagatcgt ttgtctgaat tatgcgacaa ggttacttca 120  
 gaacgtgatt ttgtagtat tacacgtcgg aatgctgaaa atgtcgtctt aatacctggt 180  
 gacgagcttt cgagtccttt agaaactgct catcttttac gtccccacg taacgtgaa 240  
 cgtttgctaa gggctttaga tagagctaaa tcaggtgttg tggaatctca aagtttggat 300  
 gatattcgta aggagttagg atttgaccaa aaagaagagt cacaaaaacc aatcaaacga 360  
 agaagttcca gtaactccaa agcaaagaaa aacagtgttt caacctga 408

<210> 37  
 <211> 246  
 <212> DNA  
 <213> Nostoc sp. PCC 7120

<400> 37  
 gtgtttcaac ctgaattttt agaagactta gaattttggg tagaaactaa tcaacgagtt 60  
 gccttaaagg ctttggtatc tgtcaaagag acttgccgag atccttttaa gggaaaaggc 120  
 aagcctgaac ctttaaaata tttagatcct gatacttggg ctgcgtcatt aacgcaagaa 180  
 catagaattg tataccttgt taaagacgat gaaataaatt ttttacaagc ccgctatcat 240  
 tattaa 246

<210> 38  
 <211> 255  
 <212> DNA  
 <213> Pseudomonas fluorescence

<400> 38  
 atggacacta tcaactacac cacagctcgt gcgcacttgg ctgaaaccat ggatcgcgtg 60  
 aatgaagact gcgccccgct tctggtaacc cgacaaaaag gcgagcctgt agtgatgatg 120  
 tctctggcgg aatacaacgc gctggaagaa acggcttata tgctgcgttc tccggccaat 180  
 ggcgagcgtg tgatcaaata aattggcgaa atgcgcgctg gaaaagccaa agtcaggcaa 240  
 ctgattgaag aatga 255

<210> 39  
 <211> 255  
 <212> DNA  
 <213> Pseudomonas fluorescence

<400> 39  
 atgaaatcc agttcacgcc aacgggctgg gaagactact tatggtttca acaaaacgat 60  
 aaggccggtc tcaaacgaat caatcttttg atcaaagcga tccagcgcca accctttgaa 120  
 ggcttgggca aaccggagcc gctcaagcac aacatgagcg gcttctggtc acggcggata 180  
 actgcccagc atcgcttggg ctatgcgata gtagacggcg aaatctgcgt cataacttgc 240

agatttcact actga 255

<210> 40  
 <211> 285  
 <212> DNA  
 <213> *Pseudomonas putida*

<400> 40  
 atgcacgtac tgacttttag ccaggctcgc gccgaactga agcagacaat ggatgatgtt 60  
 tgccgggacc atgagcccgc cgtaatcacg cgacagcgtg gccaacccgt agtgatgatg 120  
 tctctggagg actacaacgg gatgaacgag accattcacc tgttgggacg gtccaaaaac 180  
 gcttcgcgct tgcgctcacc catcgctcag ctccgggacg gccaggcctt gacgaaggaa 240  
 ctggacctca atgagcaaga accagaagca gccgaacaag aatga 285

<210> 41  
 <211> 255  
 <212> DNA  
 <213> *Pseudomonas putida*

<400> 41  
 gtgaagtcca ccaaggaggg ctgggaggat tactgtcact ggcagaatgc cgacctcacc 60  
 atcctcggca acatcaacgc cctaattgac gtgtgcctac gcacccccctt caccgggtatt 120  
 ggcaagcctg agccgctgaa aggcgattta tctggcttgt ggtcccgccg catcacccgt 180  
 gagcaccgcc tggctactt ctccgaggcc ggtatgctca ccgttctgca atgccgctac 240  
 cactacgacg actaa 255

<210> 42  
 <211> 279  
 <212> DNA  
 <213> *Pseudomonas syringae*

<400> 42  
 atgcagggtt tatcattcag ccaggctcgc gccggtttaa agcaagcgat ggatgatgtg 60  
 tgccgggacc atgagccagc actcatcaca cgcctgcgag gtgatcatgt agtcatgctt 120  
 tcccttgatg actacaactc gatgtcagaa accatgtacc tgctaggcac agaggccaat 180  
 gccgaagcacc tgcggcaatc cattgcgcag cacaaagccg gaaaagcctt cgtaaaggaa 240  
 atttactggt atgtcacagg gtcagaaaca gaagaataa 279

<210> 43  
 <211> 249  
 <212> DNA  
 <213> *Pseudomonas syringae*

<400> 43  
 gtgcatttca ccctatcggt atgggatgat tacactcact ggaaggatgc cgatcaggca 60  
 atttccctgt caatagacag cctcattagc cagtgcctgc gtacgccggtt caaaggcacc 120  
 ggtaagccga gacctgac cggcgattta accgggtact ggtcccgccg catcaccaaa 180  
 gagcatcgtc ttgtctactt ctatgagggc ggtgtactga cagtcacgcg gtgtcgccat 240  
 cattactag 249

<210> 44  
 <211> 195  
 <212> DNA  
 <213> *Rickettsia conorii*

<400> 44  
 atgaactcaa ttagcggcac ttcatctaga aaaaacttaa gctotgtact aaataccgta 60

## 10

gaaaacgatac atgtccctta tcttattaaa agaaagaatc ataagaatat tattctttta 120  
 accgaagaag aatatgaatc tacaaaagaa acattatatt tattatctaa tctggggcta 180  
 atgcgaatcg aataa 195

<210> 45  
 <211> 234  
 <212> DNA  
 <213> *Rickettsia conorii*

<400> 45  
 acactagaat cagcggagga tttagcgtat tggaaaaat acgatattaa aaaatatgaa 60  
 cgtattaaac ttctaataaa aaatatccaa gaagcaccgg ttacaggat aggtaagccc 120  
 gaacctttta aacatatatt atcaggttta tggtcacgta gaattaacca cgaacataga 180  
 ctaatatatt ctgtcaatac taaacaaatt ataatatata attgtagctt tcat 234

<210> 46  
 <211> 228  
 <212> DNA  
 <213> *Salmonella typhi*

<400> 46  
 atgtttatgc gtacgggtta ctatagcgaa gcgcggcaaa atctggcga agtcctggaa 60  
 agtgccgtga cgggggggccc tgttaccatc acgcgtcgtg ggcataagtc cgcagtgatc 120  
 atcagcgcg aggagtttga gcgttatcag acggcgcgaa tggatgatga gtttgctgcc 180  
 attatggcgg ttcattggcaa tgagctcagg gagctggcgg ataaatga 228

<210> 47  
 <211> 369  
 <212> DNA  
 <213> *Salmonella typhi*

<400> 47  
 atgaccttac aacttatctc agcggagag ataattcagt ttcacgacag gcttctccgc 60  
 gttacgcctg gtgtaacagg catgcctgat cctggccgcg cggaagcgct aatgtaccgg 120  
 gtactcaagc aaatcgaata tgaaggggtg accgacgtgt ggctgctggc ggcaatgcac 180  
 ttgctcgcta tatcccgtgg gcatatcttc aatgatggta acaaacgtac cgccttattt 240  
 attacgctgc tgttttttaa gcgtaacggg atctcactcg ctgcgaatcc ggattttgtc 300  
 gatatgacag tegatgcggc ggcagggcgg cttacgctgg agcaaattgc cgttcgctta 360  
 cgtgcctga 369

<210> 48  
 <211> 252  
 <212> DNA  
 <213> *Streptococcus aureus*

<400> 48  
 atgattatta aaaattattc atacgctcga cagaatttaa aggcacttat gacaaaagta 60  
 aatgatgata gtgatatggt aactgtaaca tctactgatg ataaaaacgt agtaatcatg 120  
 toagaatcag attataactc catgatggaa acactttacc tccaacagaa cccaaataat 180  
 gctgaacact tagotcaatc aattgcagat ctagaacgtg ggaaaactat aacgaaagat 240  
 atagatgtat aa 252

<210> 49  
 <211> 267  
 <212> DNA  
 <213> *Streptococcus aureus*



11

<400> 49  
 atggctaggt taaatattac gttttcgct caagccttg aagattataa gtattttcag 60  
 cagaacaata aaaaatggg gaagaagatt aatgagttac ttaaaagtat tgacagaaat 120  
 ggtgcattgg aaggtatagg taagcctgaa aagttaaaat cgaatctgac tgggtattat 180  
 agtagacgta tcaatcacga acatagattg gtttatacag tagatgacaa tcatataaaa 240  
 atagcatcat gtaaatacca ttattaa 267

<210> 50  
 <211> 255  
 <212> DNA  
 <213> *Streptococcus pneumoniae*

<400> 50  
 atggaagcag tcctttactc aacattccga aatcatttaa aggactacat gaagaaggta 60  
 aatgatgaat ttgagccttt gacggtgggc aataaaaatc cagatgagga cattgtagtc 120  
 ctttcaaaga gtgagtggga tagtatcaa gaaaccctga gaattgctca aaataaggaa 180  
 ctttctgata aggttttgcg aggaatggct caagttcgtg ctggaagtac tcaggtccat 240  
 gttattgagg agtaa 255

<210> 51  
 <211> 255  
 <212> DNA  
 <213> *Streptococcus pneumoniae*

<400> 51  
 atgctgtcca agtttacaga agatgcctgg gcagattatt gctactggca aaatcaggat 60  
 aagaaaacgt taaaagaat caataaacta atcaaggata ttcaacgtga tccctttaca 120  
 ggaataggta aaccagaacc actcaaata gattaccaag gagcctggc acggcgtatt 180  
 gatgcagaaa atcgcttgat ttatatgat gatggagata gcgtggcttt cttgtccttt 240  
 aaagatcatt actaa 255

<210> 52  
 <211> 264  
 <212> DNA  
 <213> *Streptomyces coelicolor*

<400> 52  
 atgtccatca ccgccagcga agcccgctcag aacctgttcc cgctgataga gcaggccaac 60  
 gaggaccacg ccccggtgca catcacctcc cgcaagggga acgccgtgct catgtccgag 120  
 gaggacttca cggcgtggac ggagacggtg catctcctgc gctcgccgag gaacgccgc 180  
 cgtctgctcg actccatcgc ggaggccgag gcgggcgacg cgactgagca cgacctgac 240  
 gacctggacg cggagcgggc gtga 264

<210> 53  
 <211> 255  
 <212> DNA  
 <213> *Streptomyces coelicolor*

<400> 53  
 gtgaggatca ctttcacgtc ccacggctgg gaggactacg tccactgggc cgagagcgac 60  
 cggaaggatga ccaagcggat caacagactg atcgccgaca tcgcccgtga cccgttcaag 120  
 ggcgtcggca agcgggagcc gctcaagggc gacctgtccg gctactggtc acgggcgcac 180  
 gacgacacgc accgtcttgt gtacaagccc accgatgacc agctggatcat cgtccaggcg 240  
 cgctaccact actga 255

12

<210> 54  
 <211> 282  
 <212> DNA  
 <213> *Streptomyces viridochromogenes*

<400> 54  
 atgtcgataa accgcgagcg aagccgcaag gctctctttc cgctgatcaa gaagggtcaac 60  
 gacaatcacg agggccatcga gatcgtctcc aagcacggca acgccgtact cgtctcggcc 120  
 gaggattatg cagcgctgcy cgagggctcg tacctgctgc gctctccggc gaacgcccggt 180  
 cgactgctca aggcgtacga gaacgccctt gccacgtca atgtgtcggg gcgggagctg 240  
 atcgatccgg attcggcgga cgtggttcg ggtgcccggt ga 282

<210> 55  
 <211> 255  
 <212> DNA  
 <213> *Streptomyces viridochromogenes*

<400> 55  
 gtgaggcttg tcttcgagga tcagggctgg gatgactaca cgtcctggct caagaacgac 60  
 cgcaagatgc tcgcccgcat caacaagctc atcgaggacg tcaggcgcgga ccccttcacg 120  
 gggatcggca aaccgcgagcc gctgaagtac cacttgccgg gggcggtggc gcggcgatc 180  
 gacgaagaa accgcctcgt gtacctggtt acggacaagg agatcgtgat cctcgctgcc 240  
 cgggtaccact actga 255

<210> 56  
 <211> 303  
 <212> DNA  
 <213> *Synechocystis* sp. PCC 7942

<400> 56  
 ttggctaagt gctattgttg tacaacaagc tgtacaactc ctcggctcat gaaagttggt 60  
 tccttcagtg acgcoagaaa aaatctcaag actgtcttgg atgaagtcgt caacgacgct 120  
 gactacacga tcattactcg ccgcaatgcc gaggaagtcg tggatcatgtc cctcgactcc 180  
 ttcaatagcc tgatcgaaac cttccacctg ctcaaatccc ctgccaatgc tgctcaccta 240  
 caacgctcga tcgctcagta ccagcaaggt caaacagtcg agcgaaatct attagatgcy 300  
 taa 303

<210> 57  
 <211> 264  
 <212> DNA  
 <213> *Synechocystis* sp. PCC 7942

<400> 57  
 atgcgtaagc tggcttggac aaacgaggct tgggaagatt acctgtattg gcaagggcag 60  
 gacaagaaga ccttaaatcg catcaacaag ctcattacog aaaccttgcg atcgcccttt 120  
 gaggggattg gtaagocaga agcgctcagg gagaacctga ctgggttttg gtcacgcgcg 180  
 attgacgaca ccaatcgctt agtttacgca gtagcagatg actacctgac cattatttcc 240  
 tgctgctacc actacagcga ttaa 264

<210> 58  
 <211> 264  
 <212> DNA  
 <213> *Synechocystis* sp. PCC 6803 A

<400> 58  
 atgaaagcaa ttacaaccac ccaagccaaa gatcatttgg atgaattaat taatgctgtc 60  
 atttctgac tagaaccac catcggttagc aacaatcaag gtcagcaggc ggtattaata 120

## 13

tcattggatg aatttaattc ttggcaagaa accotttact tactetctaa tccaaccaac 180  
 goagaacatt taatggcato gattaagcaa gctgaaactg gacagatcat taagcaaaaa 240  
 ttaccagatt tattggaact gtga 264

<210> 59  
 <211> 261  
 <212> DNA  
 <213> *Synechocystis* sp. PCC 6803 A

<400> 59  
 gtgaaaatcg cctttaccga gctatcttgg catgattacc tctggtttca gcaaaatgat 60  
 aaaaaacttc tcaaaagaat taatttactc attaaggcaa ttgcoaggga tctttttgat 120  
 ggtataggaa aaccagaacc actcaaagca aatctttcgg gttactggtc gaggcgcatc 180  
 aattctgagc atcgtttggg gtacacgatt gctgategag atttactaat tttttcctgc 240  
 cgattccatt atcaaaggta a 261

<210> 60  
 <211> 264  
 <212> DNA  
 <213> *Synechocystis* sp. PCC 6803 B

<400> 60  
 atggaaacca ttaattatca acaattctct gaaaaactgc ccacttttgg agaaaaaata 60  
 ggtaatgagc aagaacctct ctgtctagag ctcccggaatt atttacgagc tgttattata 120  
 tctgagcaag attaccgtag tttgatggaa actgtttatc tgttgagtaa ccctgttaat 180  
 gctgaaaagt tattaactac cgctagtcga tcaattgac aagctacatc gtggacaaaa 240  
 gtaaaaaatg acttaggact atga 264

<210> 61  
 <211> 261  
 <212> DNA  
 <213> *Synechocystis* sp. PCC 6803 B

<400> 61  
 atgaaggaag ttgtttttaga ttgcgaggca attgaagata taaagtgggt gattcaacaa 60  
 gataaaaagt tagcgtaaa aatcatggaa ttaattgaga cgctaccaa atcacctttt 120  
 gccggcaag gaaaaccaga aaaacttcgt ttaatttgt caggtttttg gccacggcgc 180  
 attactcaag agcatcgct agtttacgaa gtcaccgatg atttcattcg tgttgtcagt 240  
 tgtcgttatc attaccgata g 261

<210> 62  
 <211> 243  
 <212> DNA  
 <213> *Tiobacillus ferrooxidans*

<400> 62  
 atgtccaccc tcaactgcaag cgaagcacgc gccaacctat atcggtcat tgaccaagcc 60  
 gctgagtcac atcagcccat ttatatcgcc ggaaagcgga caagtgcggt ccttctctcc 120  
 acggaagatt ggggaagcaat ccaagaaaca ctatactcc tttccgttcc gggcagcgcc 180  
 gaatctatca aggaggggtat ggctgagccc cttagcaaga gcaatatgga cctcaagtgg 240  
 tga 243

<210> 63  
 <211> 252  
 <212> DNA  
 <213> *Tiobacillus ferrooxidans*

## 14

<400> 63  
 gtgggtctatt cgaacacgc gcagaaggat gcgaagaagc tggcggctgc tggcttaaaa 60  
 aacaacgcaa tagaactcot ggcggttctt gccgccgac catttcagaa ccgcccaccc 120  
 tacgagaatc tcgtaggcga cctcgccggc gcgatttcac gacgcataca cattoagcat 180  
 cgtttgggtt atgaagtctt tccaaaggag cgagtgggtc gogtgttgcg catgtggacg 240  
 cactatgagt ga 252

<210> 64  
 <211> 252  
 <212> DNA  
 <213> *Yersinia enterocolitica*

<400> 64  
 atgagaacaa ttagttatag tgaagcggc cagaatttgt cgacaacgat ggtgcaaacg 60  
 gttgaggatc gagccccat cctcatcacc cgtcaaatg ggacttcttg tgttcttatg 120  
 tcacttgaag aatatgaatc attggaagaa actgcttatt tattgcgttc accagcaaac 180  
 gcgaagcact tgatggactc aattgaagag ttgagagcag gaaaaggaat tcaaagggaa 240  
 cttgaagcgt ga 252

<210> 65  
 <211> 255  
 <212> DNA  
 <213> *Yersinia enterocolitica*

<400> 65  
 gtgaaaatta tattttccag ttgttcttgg gaggattato tttattggca acaaacggat 60  
 aagaaaatcc tcaaacgcat taatgggtta gtaaaaaata ttcaaagaac gccatttgag 120  
 gtaaagggca aaccagaacc ccttaaacat aatctggcag ggttctggtc acggaggatg 180  
 acagaagagc acagacttgt ttatgaggtt tccggtgata atttattaat tgctgottat 240  
 cgttactatt attga 255

<210> 66  
 <211> 210  
 <212> DNA  
 <213> *Yersinia enterocolitica*

<400> 66  
 atgaatagca tcagttatac agccgcaaga aataatttag ccaaggtatt attggaagca 60  
 caaaagcagc ccgtagaat cagcgccgt gggcagagt aggtctatat tatcagcaag 120  
 gctgattatg aggatttgat gaaagcaaag gtaaaggcac atattcaatt taaacatgca 180  
 gaaaccatta aagctcttgc tgatagatga 210

<210> 67  
 <211> 357  
 <212> DNA  
 <213> *Yersinia enterocolitica*

<400> 67  
 atgatatttt taacggcaaa tgatattgcg gaggtttaac cagaaattat ccctaacggc 60  
 aggcctgata atagtaagat tgaggctgta gccagccgag tattaatgc acatcattat 120  
 gacaacgtgg atgatgtata tcagttagcc gctatctact taattgccat tagtcgaggt 180  
 cacatttttc ttgatgggaa caagcgcaac gcatttcaaa gcattggcgt gttccttggt 240  
 ataaatggcg tagacctgtg tgcaagcaat caactggaag aattaaccgt tgaagcagcg 300  
 caaggaaaaa ttggtgttga gcagataacg gaacagttac gcgagcttac cgagtaa 357

15

<210> 68  
 <211> 83  
 <212> PRT  
 <213> Actinobacillus actinomycetemcomitans

<400> 68

Met Asn Val Ile Ser Tyr Ser Ala Phe Arg Ala Glu Leu Ala Thr Thr  
 1 5 10 15

Leu Asp Gln Val Val Ala Asp His Ser Pro Val Met Ile Thr Arg Gln  
 20 25 30

Asn Gly Lys His Ala Val Val Met Ser Leu Glu Asp Phe Ala Ala Tyr  
 35 40 45

Glu Glu Thr Ala Tyr Leu Leu Arg Ser Pro Lys Asn Arg Glu Arg Leu  
 50 55 60

Leu Ala Ser Ile Asp Gln Leu Asn Ser Gly Lys Ile Ile Glu Arg Glu  
 65 70 75 80

Leu Gln Glu

<210> 69  
 <211> 84  
 <212> PRT  
 <213> Actinobacillus actinomycetemcomitans

<400> 69

Met Ile Leu Ala Trp Thr Glu Thr Ala Trp Glu Asp Tyr Leu Tyr Trp  
 1 5 10 15

Gln Gln Val Asp Lys Lys Thr Leu Leu Arg Ile Asn Lys Leu Ile Gln  
 20 25 30

Asn Ile Thr Arg Ser Pro Phe Glu Gly Leu Gly Asn Pro Lys Pro Leu  
 35 40 45

Lys His Gln Leu Ser Gly Phe Trp Ser Arg Arg Ile Asp Lys Glu His  
 50 55 60

Arg Leu Val Tyr Gln Val Ser Asp Ser His Leu Thr Ile Ile Gln Cys  
 65 70 75 80

Arg Tyr His Tyr

<210> 70  
 <211> 84  
 <212> PRT  
 <213> Agrobacterium tumefaciens

<400> 70

Met Ala Asn Val Arg Phe Thr Glu Phe Arg Gln Asn Phe Ala Thr His  
 1 5 10 15

Phe Asp Arg Val Leu Glu Thr Arg Ala Pro Leu Leu Val Thr Arg Gln  
 20 25 30

Gly Lys Glu Ala Val Val Val Leu Ala Glu Gly Glu Tyr Glu Ser Met  
 35 40 45

16

Gln Glu Thr Leu His Leu Leu Ser Asn Pro Ala Asn Ala Ser Arg Leu  
50 55 60

Arg Ala Ser Met Gly Glu Leu Glu Arg Gly Asp Thr Ile Glu Arg Asp  
65 70 75 80

Pro Thr Glu Glu

<210> 71  
<211> 89  
<212> PRT  
<213> *Agrobacterium tumefaciens*

<400> 71

Met Lys Leu Val Trp Thr Leu Ser Ser Trp Asp Asp Tyr Glu Phe Trp  
1 5 10 15

Gln Arg Thr Asp Ala Arg Met Val Glu Lys Ile Asn Asp Leu Ile Arg  
20 25 30

Asn Ala Lys Arg Thr Pro Phe Ala Gly Leu Gly Lys Pro Glu Pro Leu  
35 40 45

Lys Gly Asp Met Ala Gly Tyr Trp Ser Arg Arg Ile Thr Ala Glu His  
50 55 60

Arg Phe Val Tyr Arg Val Ser Gly Ser Gly Ser Glu Gln Arg Leu Glu  
65 70 75 80

Val Ile Gln Cys Arg Phe His Tyr Gln  
85

<210> 72  
<211> 82  
<212> PRT  
<213> *Burkholderia cepacia*

<400> 72

Met Asn Val Leu Thr Tyr Ser Glu Ala Arg Ala Gly Phe Lys Gln Ala  
1 5 10 15

Met Asp Asp Val Cys Arg Asp His Ile Pro Met Leu Ile Thr Arg Gln  
20 25 30

Thr Gly Glu Asn Val Val Met Val Ser Leu Ala Asp Phe Asn Ala Met  
35 40 45

Gln Glu Thr Leu Tyr Leu Leu Ser Ser Ser Lys Asn Ala Gln Arg Leu  
50 55 60

Ala Arg Ser Ile Ala Gln Leu Asn Ala Gly Gly Ala Thr Ala Arg Glu  
65 70 75 80

Leu Leu

<210> 73  
<211> 83  
<212> PRT  
<213> *Burkholderia cepacia*

17

&lt;400&gt; 73

Met Phe Thr Asp Asp Ala Trp Asp Asp Tyr Leu Tyr Trp Gln Glu Thr  
 1 5 10 15

Asp Arg Lys Val Val Arg Lys Ile Asn Thr Leu Leu Glu Glu Cys Arg  
 20 25 30

Arg Asp Pro Tyr Arg Gly Thr Gly Lys Pro Glu Ala Leu Met Gly Ser  
 35 40 45

Met Ser Gly Leu Trp Ser Arg Arg Ile Thr Leu Ala Asp Arg Leu Val  
 50 55 60

Tyr Leu Pro Arg Asp Gly Lys Ile Tyr Val Ile Ala Phe Arg Phe His  
 65 70 75 80

Tyr Asp Cys

&lt;210&gt; 74

&lt;211&gt; 84

&lt;212&gt; PRT

<213> *Coxiella burnetii*

&lt;400&gt; 74

Met Asn Val Val Thr Phe Ser Glu Leu Arg Ala Gln Leu Lys Lys Ile  
 1 5 10 15

Leu Asp Leu Ser Ala Asp Gln His Glu Pro Val Val Val Lys Arg Pro  
 20 25 30

Asn Lys Glu Thr Met Val Ile Leu Ser Leu Arg Asp Phe Glu Ala Leu  
 35 40 45

Lys Glu Thr Ala Tyr Leu Leu Ser Asn Glu Ala Asn Ala Ala Arg Leu  
 50 55 60

Arg Gln Ser Ile Arg Ser Leu Lys Gln Gly Lys Ala Gln Lys Lys Lys  
 65 70 75 80

Leu Met Glu Asp

&lt;210&gt; 75

&lt;211&gt; 91

&lt;212&gt; PRT

<213> *Coxiella burnetii*

&lt;400&gt; 75

Met Gln Ile Ser Phe Thr Pro Glu Ala Trp Glu Asp Tyr Leu Tyr Trp  
 1 5 10 15

Gln Lys Phe Asp Lys Lys Met Leu Arg Arg Ile Asn Glu Leu Ile Lys  
 20 25 30

Asp Ala Met His Glu Pro Phe Ser Gly Lys Gly Lys Pro Glu Pro Leu  
 35 40 45

Lys Phe Glu Leu Gln Gly Tyr Trp Ser Arg Arg Leu Asp Gln Glu His  
 50 55 60

18

Arg Leu Val Tyr Lys Val Leu Asp Asp Ser Leu Met Ile Ile Ala Ala  
65 70 75 80

Arg Phe His Tyr Asn Arg Leu Asn Ser Lys Asn  
85 90

<210> 76  
<211> 92  
<212> PRT  
<213> Escherichia coli  
<400> 76

Met Asn Cys Thr Lys Glu Glu Ile Asp Met Arg Thr Ile Ser Tyr Ser  
1 5 10 15

Glu Ala Arg Gln Asn Leu Ser Ala Thr Met Met Lys Ala Val Glu Asp  
20 25 30

His Ala Pro Ile Leu Ile Thr Arg Gln Asn Gly Glu Ala Cys Val Leu  
35 40 45

Met Ser Leu Glu Glu Tyr Asn Ser Leu Glu Glu Thr Ala Tyr Leu Leu  
50 55 60

Arg Ser Pro Ala Asn Ala Arg Arg Leu Met Asp Ser Ile Asp Ser Leu  
65 70 75 80

Lys Ser Gly Lys Gly Thr Glu Lys Asp Ile Ile Glu  
85 90

<210> 77  
<211> 84  
<212> PRT  
<213> Escherichia coli  
<400> 77

Met Lys Leu Ile Trp Ser Glu Glu Ser Trp Asp Asp Tyr Leu Tyr Trp  
1 5 10 15

Gln Glu Thr Asp Lys Arg Ile Val Lys Lys Ile Asn Glu Leu Ile Lys  
20 25 30

Asp Thr Arg Arg Thr Pro Phe Glu Gly Lys Gly Lys Pro Glu Pro Leu  
35 40 45

Lys His Asn Leu Ser Gly Phe Trp Ser Arg Arg Ile Thr Glu Glu His  
50 55 60

Arg Leu Val Tyr Ala Val Thr Asp Asp Ser Leu Leu Ile Ala Ala Cys  
65 70 75 80

Arg Tyr His Tyr

<210> 78  
<211> 89  
<212> PRT  
<213> Enterococcus faecium  
<400> 78

Met Glu Ala Val Ala Tyr Ser Asn Phe Arg Gln Asn Leu Arg Ser Tyr  
1 5 10 15



19

Met Lys Gln Val Asn Glu Asp Ala Glu Thr Leu Ile Val Thr Ser Lys  
20 25 30

Asp Val Glu Asp Thr Val Val Val Leu Ser Lys Arg Asp Tyr Asp Ser  
35 40 45

Met Gln Glu Thr Leu Arg Thr Leu Ser Asn Asn Tyr Val Met Glu Lys  
50 55 60

Ile Arg Arg Gly Asp Glu Gln Phe Ser Lys Gly Ala Phe Lys Thr His  
65 70 75 80

Asp Leu Ile Glu Val Glu Ser Asp Asp  
85

<210> 79  
<211> 85  
<212> PRT  
<213> Enterococcus faecium

<400> 79

Met Ile Lys Ala Trp Ser Asp Asp Ala Trp Asp Asp Tyr Leu Tyr Trp  
1 5 10 15

His Glu Gln Gly Asn Lys Ser Asn Ile Lys Lys Ile Asn Lys Leu Ile  
20 25 30

Lys Asp Ile Asp Arg Ser Pro Phe Ala Gly Leu Gly Lys Pro Glu Pro  
35 40 45

Leu Lys His Asp Leu Ser Gly Lys Trp Ser Arg Arg Ile Thr Asp Glu  
50 55 60

His Arg Leu Ile Tyr Arg Val Glu Asn Glu Thr Ile Phe Ile Tyr Ser  
65 70 75 80

Ala Lys Asp His Tyr  
85

<210> 80  
<211> 85  
<212> PRT  
<213> Francisella tularensis

<400> 80

Met Gln Thr Val Asn Tyr Ser Thr Phe Arg Asn Glu Leu Ser Asp Ser  
1 5 10 15

Met Asp Arg Val Thr Lys Asn His Ser Pro Met Ile Val Thr Arg Gly  
20 25 30

Ser Lys Lys Glu Ala Val Val Met Met Ser Leu Glu Asp Phe Lys Ala  
35 40 45

Tyr Glu Glu Thr Ala Tyr Leu Met Arg Ser Met Asn Asn Tyr Lys Arg  
50 55 60

Leu Gln Asn Ser Ile Asp Glu Val Glu Ser Gly Leu Ala Ile Gln Lys  
65 70 75 80

Glu Leu Ile Glu Glu

20

85

<210> 81  
 <211> 68  
 <212> PRT  
 <213> *Francisella tularensis*

<400> 81

Met Ile Leu Ser Trp Ser Thr Asn Ala Trp Glu Asp Tyr Leu Tyr Trp  
 1 5 10 15

Gln Ser Ile Asp Lys Lys Lys Leu Lys Arg Ile Asn Leu Leu Ile Lys  
 20 25 30

Asp Ile Met Arg Asn His Phe Glu Gly Leu Gly Glu Pro Glu Pro Leu  
 35 40 45

Lys His Asn Phe Ser Gly Tyr Trp Ser Arg Arg Ile Asp Lys Glu His  
 50 55 60

Leu Asn Asn Leu  
 65

<210> 82  
 <211> 73  
 <212> PRT  
 <213> *Klebsiella pneumoniae*

<400> 82

Met Arg Thr Val Asn Tyr Ser Glu Ala Arg Gln Asn Leu Ala Asp Val  
 1 5 10 15

Leu Glu Ser Ala Val Thr Gly Val Pro Val Thr Ile Thr Arg Arg Gly  
 20 25 30

His Lys Ser Ala Val Ile Ile Ser Ala Glu Glu Phe Glu Arg Tyr Gln  
 35 40 45

Ala Ala Arg Met Asp Asp Glu Phe Ala Ala Ile Met Ala Val His Gly  
 50 55 60

Asp Glu Ile Arg Glu Leu Ala Asp Lys  
 65 70

<210> 83  
 <211> 122  
 <212> PRT  
 <213> *Klebsiella pneumoniae*

<400> 83

Met Thr Leu Gln Ile Ile Ser Ala Glu Glu Ile Ile Gln Phe His Asp  
 1 5 10 15

Arg Leu Leu Arg Val Thr Pro Gly Val Ala Gly Met Pro Asp Pro Gly  
 20 25 30

Arg Ala Glu Ala Ile Met Tyr Arg Val Leu Asn Lys Ile Glu Tyr Glu  
 35 40 45

Gly Val Thr Asp Val Trp Arg Leu Ala Ala Met His Leu Leu Ala Ile  
 50 55 60

21

Ser Arg Gly His Ile Phe Asn Asp Gly Asn Lys Arg Thr Ala Leu Phe  
65 70 75 80

Ile Thr Leu Leu Phe Leu Lys Arg Asn Gly Ile Ile Leu Pro Ala Asn  
85 90 95

Pro Asp Phe Val Gly Met Thr Val Glu Ala Ala Ala Gly Gln Leu Thr  
100 105 110

Leu Glu Gln Ile Val Ala Arg Leu Arg Gly  
115 120

&lt;210&gt; 84

&lt;211&gt; 91

&lt;212&gt; PRT

&lt;213&gt; Mycobacterium bovis

&lt;400&gt; 84

Met Ser Ile Ser Ala Ser Glu Ala Arg Gln Arg Leu Phe Pro Leu Ile  
1 5 10 15

Glu Gln Val Asn Thr Asp His Gln Pro Val Arg Ile Thr Ser Arg Ala  
20 25 30

Gly Asp Ala Val Leu Met Ser Ala Asp Asp Tyr Asp Ala Trp Gln Glu  
35 40 45

Thr Val Tyr Leu Leu Arg Ser Pro Glu Asn Ala Arg Arg Leu Met Glu  
50 55 60

Ala Val Ala Arg Asp Lys Ala Gly His Ser Ala Phe Thr Lys Ser Val  
65 70 75 80

Asp Glu Leu Arg Glu Met Ala Gly Gly Glu Glu  
85 90

&lt;210&gt; 85

&lt;211&gt; 85

&lt;212&gt; PRT

&lt;213&gt; Mycobacterium bovis

&lt;400&gt; 85

Met Arg Ser Val Asn Phe Asp Pro Asp Ala Trp Glu Asp Phe Leu Phe  
1 5 10 15

Trp Leu Ala Ala Asp Arg Lys Thr Ala Arg Arg Ile Thr Arg Leu Ile  
20 25 30

Gly Glu Ile Gln Arg Asp Pro Phe Ser Gly Ile Gly Lys Pro Glu Pro  
35 40 45

Leu Gln Gly Glu Leu Ser Gly Tyr Trp Ser Arg Arg Ile Asp Asp Glu  
50 55 60

His Arg Leu Val Tyr Arg Ala Gly Asp Asp Glu Val Thr Met Leu Lys  
65 70 75 80

Ala Arg Tyr His Tyr  
85

&lt;210&gt; 86

&lt;211&gt; 91

22

&lt;212&gt; PRT

&lt;213&gt; Mycobacterium tuberculosis

&lt;400&gt; 86

Met Ser Ile Ser Ala Ser Glu Ala Arg Gln Arg Leu Phe Pro Leu Ile  
 1 5 10 15

Glu Gln Val Asn Thr Asp His Gln Pro Val Arg Ile Thr Ser Arg Ala  
 20 25 30

Gly Asp Ala Val Leu Met Ser Ala Asp Asp Tyr Asp Ala Trp Gln Glu  
 35 40 45

Thr Val Tyr Leu Leu Arg Ser Pro Glu Asn Ala Arg Arg Leu Met Glu  
 50 55 60

Ala Val Ala Arg Asp Lys Ala Gly His Ser Ala Phe Thr Lys Ser Val  
 65 70 75 80

Asp Glu Leu Arg Glu Met Ala Gly Gly Glu Glu  
 85 90

&lt;210&gt; 87

&lt;211&gt; 85

&lt;212&gt; PRT

&lt;213&gt; Mycobacterium tuberculosis

&lt;400&gt; 87

Met Arg Ser Val Asn Phe Asp Pro Asp Ala Trp Glu Asp Phe Leu Phe  
 1 5 10 15

Trp Leu Ala Ala Asp Arg Lys Thr Ala Arg Arg Ile Thr Arg Leu Ile  
 20 25 30

Gly Glu Ile Gln Arg Asp Pro Phe Ser Gly Ile Gly Lys Pro Glu Pro  
 35 40 45

Leu Gln Gly Glu Leu Ser Gly Tyr Trp Ser Arg Arg Ile Asp Asp Glu  
 50 55 60

His Arg Leu Val Tyr Arg Ala Gly Asp Asp Glu Val Thr Met Leu Lys  
 65 70 75 80

Ala Arg Tyr His Tyr  
 85

&lt;210&gt; 88

&lt;211&gt; 98

&lt;212&gt; PRT

&lt;213&gt; Neisseria europea A

&lt;400&gt; 88

Met Ala Glu Cys Asn Val Gln Ile Asn Val Gln Leu Glu Asn Leu Met  
 1 5 10 15

Asp Ala Ile Thr Tyr Ser Thr Ala Arg Ala Lys Leu Ala Asp Thr Met  
 20 25 30

Asn Arg Val Cys Asp Asn His Glu Pro Ile Ile Ile Thr Arg Asn Gly  
 35 40 45

Glu Gln Ser Val Val Met Met Ser Leu Asp Asp Phe Lys Ala Leu Glu

23

50

55

60

Glu Thr Ser Tyr Leu Leu Arg Ser Pro Lys Asn Ala Lys Arg Leu Leu  
65 70 75 80

Glu Ser Ile Ala Ala Leu Glu Ser Gly Arg Gly Glu Thr Arg Ser Leu  
85 90 95

Ala Glu

<210> 89  
<211> 84  
<212> PRT  
<213> Neisseria europea A

<400> 89

Met Lys Leu Val Phe Ser Glu Gln Ala Trp Glu Asp Tyr Leu Tyr Trp  
1 5 10 15

Gln Lys Thr Asp Arg Lys Thr Val Gln Arg Ile Asp Thr Leu Val Lys  
20 25 30

Glu Ile Thr Arg Thr Pro His Glu Gly Thr Gly Lys Pro Glu Pro Leu  
35 40 45

Lys His Ala Leu Ser Gly Tyr Trp Ser Arg Arg Ile Asn Asn Glu His  
50 55 60

Arg Ile Val Tyr Lys Ile Ala Asp Asp Ser Leu Phe Ile Ala Gln Leu  
65 70 75 80

Arg Tyr His Tyr

<210> 90  
<211> 102  
<212> PRT  
<213> Neisseria europea B

<400> 90

Met Tyr Leu Phe Tyr Thr Cys Thr Ile Tyr Cys Ala Asn Glu Val Ala  
1 5 10 15

Met Lys Val Val Thr Tyr Ser His Ala Arg Asn Ala Leu Lys Ser Ile  
20 25 30

Leu Asp Asp Val Ile Gln Asp Ala Asp Val Ile Val Ile Ser Arg Arg  
35 40 45

Asp Ala Glu Gly Asp Ala Val Val Met Ser Leu Asp Ser Tyr Asn Ser  
50 55 60

Ile Met Glu Thr Leu His Leu Thr Ser Asn Pro Ala Asn Ala Ala Ala  
65 70 75 80

Leu Ala Lys Ala Ile Ala Gln Asp Lys Ala Gly Gln Ala Gln Asp His  
85 90 95

Pro Leu Leu Ser Ala Asp  
100

24

<210> 91  
 <211> 86  
 <212> PRT  
 <213> *Neisseria europea* B

<400> 91

Met Arg Ala Ile Arg Phe Val Pro Asp Ala Trp Glu Ala Tyr Leu Tyr  
 1 5 10 15

Trp Gln Asp Gln Asp Lys Lys Thr Leu Arg Arg Leu Asn Ser Leu Ile  
 20 25 30

Thr Ala Ala Ser Arg Asp Pro Phe Val Gly Ile Gly Lys Pro Glu Pro  
 35 40 45

Leu Arg Gly Glu Leu Ser Gly Tyr Trp Ser Arg Arg Ile Asp Glu Thr  
 50 55 60

Asn Arg Leu Val Tyr Arg Val Thr Asp Val Glu Leu Val Ile Ile Ala  
 65 70 75 80

Cys Arg Phe His Tyr Glu  
 85

<210> 92  
 <211> 80  
 <212> PRT  
 <213> *Neisseria europea* C

<400> 92

Met Ala Ile Leu Asn Ala Thr Glu Ala Arg Ala Arg Leu Tyr Ala Leu  
 1 5 10 15

Ile Asp Glu Ala Ala Glu Thr His Gln Pro Ile Val Ile Lys Gly Lys  
 20 25 30

Arg Ser Ser Ala Val Leu Leu Ser Glu Glu Asp Trp Asn Ala Ile Asn  
 35 40 45

Glu Thr Leu Tyr Leu Val Ser Ile Pro Gly Met Arg Glu Ser Ile Met  
 50 55 60

Glu Gly Met Lys Thr Asp Val Asp Glu Cys Ser Arg Glu Leu Asp Trp  
 65 70 75 80

<210> 93  
 <211> 86  
 <212> PRT  
 <213> *Neisseria europea* C

<400> 93

Met Trp Glu Leu Arg Tyr Thr His Gln Ala Gln Lys Asp Ala Lys Lys  
 1 5 10 15

Leu Ala Ser Ser Gly Leu Lys Asp Lys Ala Glu Glu Leu Leu Ala Val  
 20 25 30

Val Arg Asn Asn Pro Tyr Gln Thr Pro Pro Pro Tyr Glu Lys Leu Val  
 35 40 45

Gly Asp Leu Ala Gly Ala Cys Ser Arg Arg Ile Asn Ile Gln His Arg  
 50 55 60

25

Leu Val Tyr Gln Val Leu Glu Arg Glu Arg Ile Val Lys Val Leu Arg  
65 70 75 80

Met Trp Thr His Tyr Val  
85

<210> 94  
<211> 135  
<212> PRT  
<213> Nostoc sp. PCC 7120

<400> 94

Met Tyr Trp Ile Lys Phe Glu Ser Thr Gln Arg Glu Leu Leu Ile Leu  
1 5 10 15

Met Leu Ser Asn Thr Tyr Thr Tyr Thr Gln Ala Arg Asp Arg Leu Ser  
20 25 30

Glu Leu Cys Asp Lys Val Thr Ser Glu Arg Asp Phe Val Val Ile Thr  
35 40 45

Arg Arg Asn Ala Glu Asn Val Ala Leu Ile Pro Val Asp Glu Leu Ser  
50 55 60

Ser Leu Leu Glu Thr Ala His Leu Leu Arg Ser Pro Arg Asn Ala Glu  
65 70 75 80

Arg Leu Leu Arg Ala Leu Asp Arg Ala Lys Ser Gly Val Val Glu Ser  
85 90 95

Gln Ser Leu Asp Asp Ile Arg Lys Glu Leu Gly Phe Asp Gln Lys Glu  
100 105 110

Glu Ser Gln Lys Pro Ile Lys Arg Arg Ser Ser Ser Asn Ser Lys Ala  
115 120 125

Lys Lys Asn Ser Val Ser Thr  
130 135

<210> 95  
<211> 81  
<212> PRT  
<213> Nostoc sp. PCC 7120

<400> 95

Met Phe Gln Pro Glu Phe Leu Glu Asp Leu Glu Phe Trp Val Glu Thr  
1 5 10 15

Asn Gln Arg Val Ala Leu Lys Ala Leu Asp Leu Val Lys Glu Thr Cys  
20 25 30

Arg Asp Pro Phe Lys Gly Lys Gly Lys Pro Glu Pro Leu Lys Tyr Leu  
35 40 45

Asp Pro Asp Thr Trp Ser Arg Arg Leu Thr Gln Glu His Arg Ile Val  
50 55 60

Tyr Leu Val Lys Asp Asp Glu Ile Asn Phe Leu Gln Ala Arg Tyr His  
65 70 75 80

26

Tyr

<210> 96  
 <211> 84  
 <212> PRT  
 <213> Pseudomonas fluorescence

&lt;400&gt; 96

Met Asp Thr Ile Asn Tyr Thr Thr Ala Arg Ala His Leu Ala Glu Thr  
 1 5 10 15

Met Asp Arg Val Asn Glu Asp Cys Ala Pro Leu Leu Val Thr Arg Gln  
 20 25 30

Lys Gly Glu Pro Val Val Met Met Ser Leu Ala Glu Tyr Asn Ala Leu  
 35 40 45

Glu Glu Thr Ala Tyr Leu Leu Arg Ser Pro Ala Asn Ala Glu Arg Leu  
 50 55 60

Ile Lys Ser Ile Gly Glu Met Arg Ala Gly Lys Ala Lys Val Arg Gln  
 65 70 75 80

Leu Ile Glu Glu

<210> 97  
 <211> 84  
 <212> PRT  
 <213> Pseudomonas fluorescence

&lt;400&gt; 97

Met Lys Ile Gln Phe Thr Pro Thr Gly Trp Glu Asp Tyr Leu Trp Phe  
 1 5 10 15

Gln Gln Asn Asp Lys Ala Gly Leu Lys Arg Ile Asn Leu Leu Ile Lys  
 20 25 30

Ala Ile Gln Arg Gln Pro Phe Glu Gly Leu Gly Lys Pro Glu Pro Leu  
 35 40 45

Lys His Asn Met Ser Gly Phe Trp Ser Arg Arg Ile Thr Ala Glu His  
 50 55 60

Arg Leu Val Tyr Ala Ile Val Asp Gly Glu Ile Cys Val Ile Thr Cys  
 65 70 75 80

Arg Phe His Tyr

<210> 98  
 <211> 94  
 <212> PRT  
 <213> Pseudomonas putida

&lt;400&gt; 98

Met His Val Leu Thr Phe Ser Gln Ala Arg Ala Glu Leu Lys Gln Thr  
 1 5 10 15

Met Asp Asp Val Cys Arg Asp His Glu Pro Ala Val Ile Thr Arg Gln  
 20 25 30



27

Arg Gly Glu Pro Val Val Met Met Ser Leu Glu Asp Tyr Asn Gly Met  
35 40 45

Asn Glu Thr Ile His Leu Leu Gly Ser Ser Lys Asn Ala Ser Arg Leu  
50 55 60

Arg Ser Ser Ile Ala Gln Leu Arg Asp Gly Gln Ala Leu Thr Lys Glu  
65 70 75 80

Leu Asp Leu Asn Glu Gln Glu Pro Glu Ala Ala Glu Gln Glu  
85 90

<210> 99  
<211> 84  
<212> PRT  
<213> *Pseudomonas putida*

<400> 99

Met Lys Phe Thr Lys Glu Gly Trp Glu Asp Tyr Cys His Trp Gln Asn  
1 5 10 15

Ala Asp Leu Thr Ile Leu Gly Asn Ile Asn Arg Leu Ile Asp Val Cys  
20 25 30

Leu Arg Thr Pro Phe Thr Gly Ile Gly Lys Pro Glu Pro Leu Lys Gly  
35 40 45

Asp Leu Ser Gly Leu Trp Ser Arg Arg Ile Thr Arg Glu His Arg Leu  
50 55 60

Val Tyr Phe Phe Glu Ala Gly Met Leu Thr Val Leu Gln Cys Arg Tyr  
65 70 75 80

His Tyr Asp Asp

<210> 100  
<211> 92  
<212> PRT  
<213> *Pseudomonas syringae*

<400> 100

Met Gln Val Leu Ser Phe Ser Gln Ala Arg Ala Gly Leu Lys Gln Ala  
1 5 10 15

Met Asp Asp Val Cys Arg Asp His Glu Pro Ala Leu Ile Thr Arg Leu  
20 25 30

Arg Gly Asp His Val Val Met Leu Ser Leu Asp Asp Tyr Asn Ser Met  
35 40 45

Ser Glu Thr Met Tyr Leu Leu Gly Thr Glu Ala Asn Ala Lys His Leu  
50 55 60

Arg Gln Ser Ile Ala Gln His Lys Ala Gly Lys Ala Phe Val Lys Glu  
65 70 75 80

Ile Ser Leu Asp Val Thr Gly Ser Glu Thr Glu Glu  
85 90

<210> 101

28

<211> 82  
 <212> PRT  
 <213> *Pseudomonas syringae*

<400> 101

Met His Phe Thr Leu Ser Gly Trp Asp Asp Tyr Thr His Trp Lys Asp  
 1 5 10 15

Ala Asp Gln Ala Ile Ser Leu Ser Ile Asp Ser Leu Ile Ser Gln Cys  
 20 25 30

Leu Arg Thr Pro Phe Lys Gly Thr Gly Lys Pro Arg Pro Leu Thr Gly  
 35 40 45

Asp Leu Thr Gly Tyr Trp Ser Arg Arg Ile Thr Lys Glu His Arg Leu  
 50 55 60

Val Tyr Phe Tyr Glu Gly Gly Val Leu Thr Val Ile Ala Cys Arg His  
 65 70 75 80

His Tyr

<210> 102  
 <211> 64  
 <212> PRT  
 <213> *Rickettsia conorii*

<400> 102

Met Asn Ser Ile Ser Gly Thr Ser Phe Arg Lys Asn Leu Ser Ser Val  
 1 5 10 15

Leu Asn Thr Val Glu Asn Asp His Val Pro Tyr Leu Ile Lys Arg Lys  
 20 25 30

Asn His Lys Asn Ile Ile Leu Leu Thr Glu Glu Glu Tyr Glu Ser Thr  
 35 40 45

Lys Glu Thr Leu Tyr Leu Leu Ser Asn Leu Gly Leu Met Arg Ile Glu  
 50 55 60

<210> 103  
 <211> 78  
 <212> PRT  
 <213> *Rickettsia conorii*

<400> 103

Thr Leu Glu Ser Ala Glu Asp Leu Ala Tyr Trp Lys Lys Tyr Asp Ile  
 1 5 10 15

Lys Lys Tyr Glu Arg Ile Lys Leu Leu Ile Lys Asn Ile Gln Glu Ala  
 20 25 30

Pro Val Thr Gly Ile Gly Lys Pro Glu Pro Leu Lys His Ile Leu Ser  
 35 40 45

Gly Leu Trp Ser Arg Arg Ile Asn His Glu His Arg Leu Ile Tyr Ser  
 50 55 60

Val Asn Thr Lys Gln Ile Ile Ile Tyr Asn Cys Ser Phe His  
 65 70 75

29

<210> 104  
 <211> 75  
 <212> PRT  
 <213> *Salmonella typhi*

<400> 104

Met Phe Met Arg Thr Val Asn Tyr Ser Glu Ala Arg Gln Asn Leu Ala  
 1 5 10 15

Glu Val Leu Glu Ser Ala Val Thr Gly Gly Pro Val Thr Ile Thr Arg  
 20 25 30

Arg Gly His Lys Ser Ala Val Ile Ile Ser Ala Glu Glu Phe Glu Arg  
 35 40 45

Tyr Gln Thr Ala Arg Met Asp Asp Glu Phe Ala Ala Ile Met Ala Val  
 50 55 60

His Gly Asn Glu Leu Arg Glu Leu Ala Asp Lys  
 65 70 75

<210> 105  
 <211> 122  
 <212> PRT  
 <213> *Salmonella typhi*

<400> 105

Met Thr Leu Gln Leu Ile Ser Ala Glu Glu Ile Ile Gln Phe His Asp  
 1 5 10 15

Arg Leu Leu Arg Val Thr Pro Gly Val Thr Gly Met Pro Asp Pro Gly  
 20 25 30

Arg Ala Glu Ala Leu Met Tyr Arg Val Leu Lys Gln Ile Glu Tyr Glu  
 35 40 45

Gly Val Thr Asp Val Trp Leu Leu Ala Ala Met His Leu Leu Ala Ile  
 50 55 60

Ser Arg Gly His Ile Phe Asn Asp Gly Asn Lys Arg Thr Ala Leu Phe  
 65 70 75 80

Ile Thr Leu Leu Phe Leu Lys Arg Asn Gly Ile Ser Leu Ala Ala Asn  
 85 90 95

Pro Asp Phe Val Asp Met Thr Val Asp Ala Ala Ala Gly Arg Leu Thr  
 100 105 110

Leu Glu Gln Ile Ala Val Arg Leu Arg Ala  
 115 120

<210> 106  
 <211> 83  
 <212> PRT  
 <213> *Streptococcus aureus*

<400> 106

Met Ile Ile Lys Asn Tyr Ser Tyr Ala Arg Gln Asn Leu Lys Ala Leu  
 1 5 10 15

Met Thr Lys Val Asn Asp Asp Ser Asp Met Val Thr Val Thr Ser Thr  
 20 25 30

30

Asp Asp Lys Asn Val Val Ile Met Ser Glu Ser Asp Tyr Asn Ser Met  
 35 40 45

Met Glu Thr Leu Tyr Leu Gln Gln Asn Pro Asn Asn Ala Glu His Leu  
 50 55 60

Ala Gln Ser Ile Ala Asp Leu Glu Arg Gly Lys Thr Ile Thr Lys Asp  
 65 70 75 80

Ile Asp Val

<210> 107  
 <211> 88  
 <212> PRT  
 <213> Streptococcus aureus

<400> 107

Met Ala Arg Leu Asn Ile Thr Phe Ser Pro Gln Ala Phe Glu Asp Tyr  
 1 5 10 15

Lys Tyr Phe Gln Gln Asn Asn Lys Lys Met Val Lys Lys Ile Asn Glu  
 20 25 30

Leu Leu Lys Ser Ile Asp Arg Asn Gly Ala Leu Glu Gly Ile Gly Lys  
 35 40 45

Pro Glu Lys Leu Lys Ser Asn Leu Thr Gly Tyr Tyr Ser Arg Arg Ile  
 50 55 60

Asn His Glu His Arg Leu Val Tyr Thr Val Asp Asp Asn His Ile Lys  
 65 70 75 80

Ile Ala Ser Cys Lys Tyr His Tyr  
 85

<210> 108  
 <211> 84  
 <212> PRT  
 <213> Streptococcus pneumoniae

<400> 108

Met Glu Ala Val Leu Tyr Ser Thr Phe Arg Asn His Leu Lys Asp Tyr  
 1 5 10 15

Met Lys Lys Val Asn Asp Glu Phe Glu Pro Leu Thr Val Val Asn Lys  
 20 25 30

Asn Pro Asp Glu Asp Ile Val Val Leu Ser Lys Ser Glu Trp Asp Ser  
 35 40 45

Ile Gln Glu Thr Leu Arg Ile Ala Gln Asn Lys Glu Leu Ser Asp Lys  
 50 55 60

Val Leu Arg Gly Met Ala Gln Val Arg Ala Gly Ser Thr Gln Val His  
 65 70 75 80

Val Ile Glu Glu

<210> 109

31

<211> 84  
 <212> PRT  
 <213> Streptococcus pneumoniae

<400> 109

Met Leu Leu Lys Phe Thr Glu Asp Ala Trp Ala Asp Tyr Cys Tyr Trp  
 1 5 10 15  
 Gln Asn Gln Asp Lys Lys Thr Leu Lys Arg Ile Asn Lys Leu Ile Lys  
 20 25 30  
 Asp Ile Gln Arg Asp Pro Phe Thr Gly Ile Gly Lys Pro Glu Pro Leu  
 35 40 45  
 Lys Tyr Asp Tyr Gln Gly Ala Trp Ser Arg Arg Ile Asp Ala Glu Asn  
 50 55 60  
 Arg Leu Ile Tyr Met Met Asp Gly Asp Ser Val Ala Phe Leu Ser Phe  
 65 70 75 80

Lys Asp His Tyr

<210> 110  
 <211> 87  
 <212> PRT  
 <213> Streptomyces coelicolor

<400> 110

Met Ser Ile Thr Ala Ser Glu Ala Arg Gln Asn Leu Phe Pro Leu Ile  
 1 5 10 15  
 Glu Gln Val Asn Glu Asp His Ala Pro Val His Ile Thr Ser Arg Lys  
 20 25 30  
 Gly Asn Ala Val Leu Met Ser Glu Glu Asp Phe Thr Ala Trp Thr Glu  
 35 40 45  
 Thr Val His Leu Leu Arg Ser Pro Arg Asn Ala Arg Arg Leu Leu Asp  
 50 55 60  
 Ser Ile Ala Glu Ala Glu Ala Gly Asp Ala Thr Glu His Asp Leu Ile  
 65 70 75 80  
 Asp Pro Asp Ala Glu Arg Ala  
 85

<210> 111  
 <211> 84  
 <212> PRT  
 <213> Streptomyces coelicolor

<400> 111

Met Arg Ile Thr Phe Thr Ser His Gly Trp Glu Asp Tyr Val His Trp  
 1 5 10 15  
 Ala Glu Ser Asp Arg Lys Val Thr Lys Arg Ile Asn Arg Leu Ile Ala  
 20 25 30  
 Asp Ile Ala Arg Asp Pro Phe Lys Gly Val Gly Lys Pro Glu Pro Leu  
 35 40 45

32

Lys Gly Asp Leu Ser Gly Tyr Trp Ser Arg Arg Ile Asp Asp Thr His  
 50 55 60

Arg Leu Val Tyr Lys Pro Thr Asp Asp Gln Leu Val Ile Val Gln Ala  
 65 70 75 80

Arg Tyr His Tyr

<210> 112  
 <211> 93  
 <212> PRT  
 <213> Streptomyces viridochromogenes

<400> 112

Met Ser Ile Asn Arg Glu Arg Ser Arg Lys Ala Leu Phe Pro Leu Ile  
 1 5 10 15

Lys Lys Val Asn Asp Asn His Glu Ala Ile Glu Ile Val Ser Lys His  
 20 25 30

Gly Asn Ala Val Leu Val Ser Ala Glu Asp Tyr Ala Ala Leu Arg Glu  
 35 40 45

Gly Ser Tyr Leu Leu Arg Ser Pro Ala Asn Ala Arg Arg Leu Leu Lys  
 50 55 60

Ala Tyr Glu Asn Ala Leu Ala His Val Asn Val Ser Glu Arg Glu Leu  
 65 70 75 80

Ile Asp Pro Asp Ser Ala Asp Ala Gly Ser Gly Ala Ala  
 85 90

<210> 113  
 <211> 84  
 <212> PRT  
 <213> Streptomyces viridochromogenes

<400> 113

Met Arg Leu Val Phe Glu Asp Gln Gly Trp Asp Asp Tyr Thr Ser Trp  
 1 5 10 15

Leu Lys Asn Asp Arg Lys Met Leu Ala Arg Ile Asn Lys Leu Ile Glu  
 20 25 30

Asp Val Arg Arg Asp Pro Phe Thr Gly Ile Gly Lys Pro Glu Pro Leu  
 35 40 45

Lys Tyr His Leu Pro Gly Ala Trp Ser Arg Arg Ile Asp Asp Glu His  
 50 55 60

Arg Leu Val Tyr Leu Val Thr Asp Lys Glu Ile Val Ile Leu Ala Ala  
 65 70 75 80

Arg Tyr His Tyr

<210> 114  
 <211> 100  
 <212> PRT  
 <213> Synechocystis sp. PCC 7942

<400> 114

33

Met Ala Lys Cys Tyr Cys Cys Thr Thr Ser Cys Thr Thr Pro Arg Leu  
1 5 10 15

Met Lys Val Val Ser Phe Ser Asp Ala Arg Lys Asn Leu Lys Thr Val  
20 25 30

Leu Asp Glu Val Val Asn Asp Ala Asp Tyr Thr Ile Ile Thr Arg Arg  
35 40 45

Asn Ala Glu Glu Val Val Val Met Ser Leu Asp Ser Phe Asn Ser Leu  
50 55 60

Ile Glu Thr Phe His Leu Leu Lys Ser Pro Ala Asn Ala Ala His Leu  
65 70 75 80

Gln Arg Ser Ile Ala Gln Tyr Gln Gln Gly Gln Thr Val Glu Arg Asn  
85 90 95

Leu Leu Asp Ala  
100

<210> 115

<211> 87

<212> PRT

<213> Synechocystis sp. PCC 7942

<400> 115

Met Arg Lys Leu Ala Trp Thr Asn Glu Ala Trp Glu Asp Tyr Leu Tyr  
1 5 10 15

Trp Gln Gly Gln Asp Lys Lys Thr Leu Asn Arg Ile Asn Lys Leu Ile  
20 25 30

Thr Glu Thr Leu Arg Ser Pro Phe Glu Gly Ile Gly Lys Pro Glu Ala  
35 40 45

Leu Arg Glu Asn Leu Thr Gly Phe Trp Ser Arg Arg Ile Asp Asp Thr  
50 55 60

Asn Arg Leu Val Tyr Ala Val Ala Asp Asp Tyr Leu Thr Ile Ile Ser  
65 70 75 80

Cys Arg Tyr His Tyr Ser Asp  
85

<210> 116

<211> 87

<212> PRT

<213> Synechocystis sp. PCC 6803 A

<400> 116

Met Lys Ala Ile Thr Thr Thr Gln Ala Lys Asp His Leu Asp Glu Leu  
1 5 10 15

Ile Asn Ala Val Ile Ser Asp Leu Glu Pro Thr Ile Val Ser Asn Asn  
20 25 30

Gln Gly Gln Gln Ala Val Leu Ile Ser Leu Asp Glu Phe Asn Ser Trp  
35 40 45

Gln Glu Thr Leu Tyr Leu Leu Ser Asn Pro Thr Asn Ala Glu His Leu

34

50

55

60

Met Ala Ser Ile Lys Gln Ala Glu Thr Gly Gln Ile Ile Lys Gln Lys  
 65 70 75 80

Leu Pro Asp Leu Leu Glu Leu  
 85

<210> 117  
 <211> 86  
 <212> PRT  
 <213> *Synechocystis* sp. PCC 6803 A

<400> 117

Met Lys Ile Ala Phe Thr Glu Leu Ser Trp His Asp Tyr Leu Trp Phe  
 1 5 10 15

Gln Gln Asn Asp Lys Lys Leu Leu Lys Arg Ile Asn Leu Leu Ile Lys  
 20 25 30

Ala Ile Ala Arg Asp Pro Phe Asp Gly Ile Gly Lys Pro Glu Pro Leu  
 35 40 45

Lys Ala Asn Leu Ser Gly Tyr Trp Ser Arg Arg Ile Asn Ser Glu His  
 50 55 60

Arg Leu Val Tyr Thr Ile Ala Asp Arg Asp Leu Leu Ile Ile Ser Cys  
 65 70 75 80

Arg Phe His Tyr Gln Arg  
 85

<210> 118  
 <211> 87  
 <212> PRT  
 <213> *Synechocystis* sp. PCC 6803 B

<400> 118

Met Glu Thr Ile Asn Tyr Gln Gln Phe Ser Glu Lys Leu Pro Thr Leu  
 1 5 10 15

Val Glu Lys Ile Gly Asn Glu Gln Glu Pro Leu Cys Leu Glu Leu Pro  
 20 25 30

Asn Tyr Leu Arg Ala Val Ile Ile Ser Glu Gln Asp Tyr Arg Ser Leu  
 35 40 45

Met Glu Thr Val Tyr Leu Leu Ser Asn Pro Val Asn Ala Glu Lys Leu  
 50 55 60

Leu Thr Thr Ala Ser Arg Ser Ile Asp Gln Ala Thr Ser Trp Thr Lys  
 65 70 75 80

Val Lys Asn Asp Leu Gly Leu  
 85

<210> 119  
 <211> 86  
 <212> PRT  
 <213> *Synechocystis* sp. PCC 6803 B

<400> 119



35

Met Lys Glu Val Val Leu Asp Ser Gln Ala Ile Glu Asp Ile Lys Trp  
 1 5 10 15

Trp Ile Gln Gln Asp Lys Lys Leu Ala Leu Lys Ile Met Glu Leu Ile  
 20 25 30

Glu Thr Leu Pro Lys Ser Pro Phe Ala Gly Lys Gly Lys Pro Glu Lys  
 35 40 45

Leu Arg Phe Asn Leu Ser Gly Phe Trp Pro Arg Arg Ile Thr Gln Glu  
 50 55 60

His Arg Leu Val Tyr Glu Val Thr Asp Asp Phe Ile Arg Val Val Ser  
 65 70 75 80

Cys Arg Tyr His Tyr Arg  
 85

<210> 120  
 <211> 80  
 <212> PRT  
 <213> *Tiobacillus ferrooxidans*

<400> 120

Met Ser Thr Leu Thr Ala Ser Glu Ala Arg Ala Asn Leu Tyr Arg Leu  
 1 5 10 15

Ile Asp Gln Ala Ala Glu Ser His Gln Pro Ile Tyr Ile Ala Gly Lys  
 20 25 30

Arg Thr Ser Ala Val Leu Leu Ser Thr Glu Asp Trp Glu Ala Ile Gln  
 35 40 45

Glu Thr Leu Tyr Leu Leu Ser Val Pro Gly Met Arg Glu Ser Ile Lys  
 50 55 60

Glu Gly Met Ala Glu Pro Leu Ser Lys Ser Asn Met Asp Leu Lys Trp  
 65 70 75 80

<210> 121  
 <211> 83  
 <212> PRT  
 <213> *Tiobacillus ferrooxidans*

<400> 121

Met Val Tyr Ser Lys His Ala Gln Lys Asp Ala Lys Lys Leu Ala Ala  
 1 5 10 15

Ala Gly Leu Lys Asn Asn Ala Ile Glu Leu Leu Ala Val Leu Ala Ala  
 20 25 30

Asp Pro Phe Gln Asn Pro Pro Tyr Glu Asn Leu Val Gly Asp Leu  
 35 40 45

Ala Gly Ala Tyr Ser Arg Arg Ile Asn Ile Gln His Arg Leu Val Tyr  
 50 55 60

Glu Val Phe Pro Lys Glu Arg Val Val Arg Val Leu Arg Met Trp Thr  
 65 70 75 80

His Tyr Glu

<210> 122  
 <211> 83  
 <212> PRT  
 <213> *Yersinia enterocolitica*

<400> 122

Met Arg Thr Ile Ser Tyr Ser Glu Ala Arg Gln Asn Leu Ser Thr Thr  
 1 5 10 15

Met Val Gln Thr Val Glu Asp Arg Ala Pro Ile Leu Ile Thr Arg Gln  
 20 25 30

Asn Gly Thr Ser Cys Val Leu Met Ser Leu Glu Glu Tyr Glu Ser Leu  
 35 40 45

Glu Glu Thr Ala Tyr Leu Leu Arg Ser Pro Ala Asn Ala Lys His Leu  
 50 55 60

Met Asp Ser Ile Glu Glu Leu Arg Ala Gly Lys Gly Ile Gln Arg Glu  
 65 70 75 80

Leu Glu Ala

<210> 123  
 <211> 84  
 <212> PRT  
 <213> *Yersinia enterocolitica*

<400> 123

Met Lys Ile Ile Phe Ser Ser Cys Ser Trp Glu Asp Tyr Leu Tyr Trp  
 1 5 10 15

Gln Gln Thr Asp Lys Lys Ile Leu Lys Arg Ile Asn Gly Leu Val Lys  
 20 25 30

Asn Ile Gln Arg Thr Pro Phe Glu Val Lys Gly Lys Pro Glu Pro Leu  
 35 40 45

Lys His Asn Leu Ala Gly Phe Trp Ser Arg Arg Met Thr Glu Glu His  
 50 55 60

Arg Leu Val Tyr Glu Val Ser Gly Asp Asn Leu Leu Ile Ala Ala Tyr  
 65 70 75 80

Arg Tyr Tyr Tyr

<210> 124  
 <211> 69  
 <212> PRT  
 <213> *Yersinia enterocolitica*

<400> 124

Met Asn Ser Ile Ser Tyr Thr Ala Ala Arg Asn Asn Leu Ala Lys Val  
 1 5 10 15

Leu Leu Glu Ala Gln Lys Gln Pro Val Glu Ile Thr Arg Arg Gly Gln  
 20 25 30

Ser Glu Val Tyr Ile Ile Ser Lys Ala Asp Tyr Glu Asp Leu Met Lys

37

35

40

45

Ala Lys Val Lys Ala His Ile Gln Phe Lys His Ala Glu Thr Ile Lys  
 50 55 60

Ala Leu Ala Asp Arg  
 65

<210> 125  
 <211> 118  
 <212> PRT  
 <213> Yersinia enterocolitica

<400> 125

Met Ile Phe Leu Thr Ala Asn Asp Ile Ala Glu Phe Asn Ala Glu Ile  
 1 5 10 15

Ile Pro Asn Gly Arg Pro Asp Asn Ser Lys Ile Glu Ala Val Ala Ser  
 20 25 30

Arg Val Leu Asn Ala His His Tyr Asp Asn Val Asp Asp Val Tyr Gln  
 35 40 45

Leu Ala Ala Ile Tyr Leu Ile Ala Ile Ser Arg Gly His Ile Phe Leu  
 50 55 60

Asp Gly Asn Lys Arg Thr Ala Phe Gln Ser Met Ala Leu Phe Leu Gly  
 65 70 75 80

Ile Asn Gly Val Asp Leu Cys Ala Ser Asn Gln Leu Glu Glu Leu Thr  
 85 90 95

Val Glu Ala Ala Gln Gly Lys Ile Gly Val Glu Gln Ile Thr Glu Gln  
 100 105 110

Leu Arg Glu Leu Thr Glu  
 115

<210> 126  
 <211> 20  
 <212> DNA  
 <213> Artificial sequence

<220>  
 <223> Antisense sequence for YefM antitoxin

<400> 126  
 ggatcggggc atgatcttca

20

<210> 127  
 <211> 21  
 <212> DNA  
 <213> Artificial sequence

<220>  
 <223> siRNA oligonucleotide

<400> 127  
 gccguugaag aucaugccct t

21

<210> 128  
 <211> 21  
 <212> DNA  
 <213> Artificial sequence

<220>

38

&lt;223&gt; siRNA oligonucleotide

&lt;400&gt; 128

gggcaugauc uucaacggct t

21

&lt;210&gt; 129

&lt;211&gt; 17

&lt;212&gt; PRT

&lt;213&gt; Artificial sequence

&lt;220&gt;

&lt;223&gt; Synthetic peptide

&lt;400&gt; 129

Arg	Thr	Ile	Ser	Tyr	Ser	Glu	Ala	Arg	Gln	Asn	Leu	Ser	Ala	Thr	Met
1				5					10					15	

Met

&lt;210&gt; 130

&lt;211&gt; 13

&lt;212&gt; PRT

&lt;213&gt; Artificial sequence

&lt;220&gt;

&lt;223&gt; Synthetic peptide

&lt;400&gt; 130

Ala	Pro	Ile	Leu	Ile	Thr	Arg	Gln	Asn	Gly	Glu	Ala	Cys
1			5						10			

&lt;210&gt; 131

&lt;211&gt; 16

&lt;212&gt; PRT

&lt;213&gt; Artificial sequence

&lt;220&gt;

&lt;223&gt; Synthetic peptide

&lt;400&gt; 131

Met	Asp	Ser	Ile	Asp	Ser	Leu	Lys	Ser	Gly	Lys	Gly	Thr	Glu	Lys	Asp
1				5					10					15	

&lt;210&gt; 132

&lt;211&gt; 20

&lt;212&gt; DNA

&lt;213&gt; Artificial sequence

&lt;220&gt;

&lt;223&gt; Single strand DNA oligonucleotide

&lt;400&gt; 4

ataatgataa cgacacgctg

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
7 April 2005 (07.04.2005)

PCT

(10) International Publication Number  
**WO 2005/031362 A3**

(51) International Patent Classification<sup>7</sup>: **G01N 33/68**,  
C12N 15/11, C07K 14/195

(21) International Application Number:  
PCT/IL2004/000898

(22) International Filing Date:  
27 September 2004 (27.09.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/507,488 2 October 2003 (02.10.2003) US  
60/550,334 8 March 2004 (08.03.2004) US

(71) Applicant (for all designated States except US): **RAMOT  
AT TEL AVIV UNIVERSITY LTD.** [IL/IL]; 32 Haim  
Levanon Street, 69 975 Tel Aviv (IL).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **GAZIT, Ehud**  
[IL/IL]; 32 Trumpeldor Street, 47264 Ramat Hasharon  
(IL). **CHERNY, Izhack** [IL/IL]; 30 Pines Street, 49 572  
Petah-Tikva (IL).

(74) Agent: **G.E. EHRLICH (1995) LTD.**; 11 Menachem Be-  
gin Street, 52 521 Ramat Gan (IL).

(81) Designated States (unless otherwise indicated, for every  
kind of national protection available): AE, AG, AL, AM,  
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,  
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,  
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,  
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,  
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,  
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,  
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,  
ZW.

(84) Designated States (unless otherwise indicated, for every  
kind of regional protection available): ARIPO (BW, GH,  
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,  
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,  
FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,  
SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,  
GW, ML, MR, NE, SN, TD, TG).

**Published:**

- with international search report
- before the expiration of the time limit for amending the  
claims and to be republished in the event of receipt of  
amendments

(88) Date of publication of the international search report:  
22 September 2005

For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.

(54) Title: NOVEL ANTIBACTERIAL AGENTS AND METHODS OF IDENTIFYING AND UTILIZING SAME

(57) Abstract: A method of identifying a molecule capable of inducing death of a bacterial cell which includes exposing toxin and antitoxin polypeptides of a toxin-antitoxin pair produced by the bacterial cell to a plurality of molecules, and identifying a molecule of the plurality of molecules capable of preventing or disrupting binding between the antitoxin and said toxin polypeptides, thereby identifying the molecule capable of inducing death of the bacterial cell.

WO 2005/031362 A3

# INTERNATIONAL SEARCH REPORT

Inter-Application No  
PCT/IL2004/000898

**A. CLASSIFICATION OF SUBJECT MATTER**  
IPC 7 G01N33/68 C12N15/11 C07K14/195

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)  
IPC 7 G01N C07K C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the International search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BIOSIS

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	GRADY R. ET AL.: "Axe-Txe, a broad-spectrum proteic toxin-antitoxin system specified by a multidrug-resistant, clinical isolate of Enterococcus faecium." MOL. MICROBIOL., vol. 47, no. 5, March 2003 (2003-03), pages 1419-1432, XP002338565 cited in the application abstract page 1424, column 1 - page 1426, column 2 figure 5  ----- -/--	1-33

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

### \* Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \* & \* document member of the same patent family

Date of the actual completion of the international search

1 August 2005

Date of mailing of the international search report

16/08/2005

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax (+31-70) 340-3016

Authorized officer

Giry, M

## INTERNATIONAL SEARCH REPORT

International Application No  
PCT/IL2004/000898

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	CHERNY I. ET AL.: "The YefM antitoxin defines a family of natively unfolded proteins." J. BIOL. CHEM., vol. 279, no. 9, 27 February 2004 (2004-02-27), pages 8252-8261, XP002338566 the whole document	1-33
P,X	ENGELBERG-KULKA H. ET AL.: "Bacterial programmed cell death systems as targets for antibiotics." TRENDS MICROBIOL., vol. 12, no. 2, February 2004 (2004-02), pages 66-71, XP002338567 the whole document	1-33
A	WO 99/58652 A (GX BIOSYSTEMS) 18 November 1999 (1999-11-18) the whole document	1-33

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/IL2004/000898

## Box II Observations where certain claims were found unsearchable (Continuation of Item 2 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 8-19  
because they relate to subject matter not required to be searched by this Authority, namely:  
Although claims 8-19 are directed to a method of treatment of the human/animal body by therapy, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

### Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.



# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/IL2004/000898

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9958652	A	18-11-1999	AU 766257 B2	09-10-2003
			AU 3596399 A	29-11-1999
			CA 2327387 A1	08-11-1999
			WO 9958652 A2	18-11-1999
			EP 1075512 A2	14-02-2001

---